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ABSTRACT 
 
The plant Hypoxis hemerocallidea, also known as the African potato, is commonly 
used as a traditional medicine to treat diabetes in South Africa. The mechanism by 
which it lowers blood glucose levels is not known. The main aim of this research was 
to study the possible hypoglycemic effect of HH using RIN-5 F pancreatic tumor 
cells. To accomplish this, the study was divided into three parts: (1) to test whether 
exposure of RIN-5F cells to glucose and HH extract affect the cell proliferation and 
cell viability, (2) to test whether the HH extract have an effect on insulin secretion, 
and (3) to test whether the HH extract has an effect on alpha amylase and alpha 
glucosiadase enzyme activity.  
 
The RIN-5F cells were exposed to different concentrations of glucose (5, 10, 20, 
37.5, 50, 55, 74, and 92.3 mM) for different times (1, 3, 6 and 24 hours). The RIN-5F 
cells were also exposed to different concentrations of HH (50, 100, 150, 200 and 500 
µ/ml) for different times (1, 3, 6 and 24 hours). Cell proliferation was evaluated using 
crystal violet staining and cell viability was evaluated using the XTT assay. To 
evaluate the effect of glucose and HH on RIN-5 F cell insulin secretion the cells were 
exposed to HH (100 μg/ml or 500 μg/ml) and / or glucose (2 mM or 50 mM) for 30 or 
90 minutes. Insulin, α-amylase activity and α-glucosidase activity were evaluated by 
using commercially available colorimetric assays. Enzymatic activity in the presence 
of HH was compared with positive controls for α-amylase activity or α-glucosidase 
activity. Results are expressed as means ± SEM or median. Statistical differences 
among groups were analyzed by analyses of variance. P < 0.05 was considered as 
significant. 
 
An increase in the cell viability and cell proliferation was found when RIN-5 F cells 
were exposed to high glucose concentrations and a high dose of HH extract for a 
short time period (1, 3 and 6 hours).When the cells were exposed to the HH extract 
over 24 hours, HH did not affect cell viability significantly. 
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 Insulin secretion from RIN-5 F cells was increased when exposed to low glucose (2 
mM) or high glucose (50 mM) for 30 minutes. Insulin secretion was increased from 
RIN5F cells after exposure to low HH (100 µg/ml) or high HH (500 µg/ml) for 30 
minutes. Exposure of RIN5-F cells to HH for 90 minutes caused a further increase in 
insulin secretion from (4.3±0.17 mIU/mg protein; P ≤ 0.01) in 100 µg/ml, to 
(7.87±0.17 mIU/mg protein; P ≤ 0.001) in 500 µg/ml. At both 30 minutes and 90 
minutes, insulin secretion was significantly higher when cells where exposed to 500 
µg/ml HH compared to 100 µg/ml HH. Insulin secretion by cells exposed to 2 mM 
glucose + 100 μg/ml HH (4.69±0.16 mIU/mg protein; P ≤ 0.001) was significantly 
higher than when exposed to 2 mM glucose only (2.27±0.17 mIU/mg protein), while 
the insulin secretion in 2 mM glucose + 500 μg/ml HH (2.56±0.17 mIU/mg protein; P 
> 0.05) was not significantly different from that in 2 mM glucose treated cells 
(2.27±0.17 mIU/mg protein). Similar results are obtained after 90 minutes. In the 
presence of high-glucose (50 mM), at both 30 minutes and 90 minutes, insulin 
secretion was significantly decreased when cells where exposed to low concentration 
of HH (100 µg/ml) and high concentration of HH (500 µg/ml).  
 
The HH extract produced α-amylase enzyme inhibition. The maximum inhibition was 
at a concentration of 10µg/ml (922±117U/ml; P ≤ 0.01). The 5 µg/ml concentrations 
failed to produce significant inhibition. The HH extract had significant α- glucosidase 
inhibitory activity at a concentration of 5µg/ml (0.12±0.3U/ml; P ≤ 0.001) or 10µg/ml 
(0.13±0.3U/ml; P ≤ 0.001). 
 
In conclusion, based on its ability to inhibit α-amylase and α- glucosidase activity HH 
has the potential to be used in control of blood glucose levels. The HH aqueous 
extract increased insulin secretion under our basic experimental conditions and in the 
presence of low glucose levels, but not at high (50 mM) glucose concentrations. 
Insulin secretion in the presence of different glucose concentrations, in the presence 
of HH, needs further investigation. It is recommended that the ability of HH to 
stimulate insulin secretion be evaluated at 15-20 mM glucose. 
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Chapter I 
 
1 Introduction 
 
The blood glucose level is regulated as part of metabolic homeostasis (Young, 1977). 
The glucose in the plasma is regulated between 3.5-8.0 mM (Arciero et al., 1999). 
Blood sugar levels outside the normal range may be an indicator of a medical 
condition. A persistently high level in blood glucose is referred to as hyperglycemia 
and low glucose levels are referred to as hypoglycemia (Colberg & Colberg, 2009; 
Lee et al., 2005). Glucose transported from the intestines or liver to the body cells is 
made available for uptake by absorption cells and metabolism (Reddy, 2012). 
 
The islets of Langerhans in the pancreas coordinates the secretion of glucagon and 
insulin (Lowell & Shulman, 2005; Quesada et al., 2008). In the event that the blood 
glucose levels rise the β-cells import and oxidise glucose to support mitochondrial 
ATP synthesis. This process prompts a rise in the cytoplasmic ATP/ ADP ratio, 
which consequently induces the Ca
2+
 uptake from mitochondria followed by a release 
of insulin (Maechler et al., 2010; MacDonald et al., 2005). After its release the 
insulin ensures the uptake of glucose from sensitive tissues, metabolism and storage 
of glucose as glycogen or lipids. Insulin has the ability to counteract the effects of 
glucagon in the liver. This occurs by inhibition of gluconeogenesis and 
glycogenolysis. Low blood glucose levels prompt the secretion of glucagon which in 
turn induces glyconeogenesis and glucose mobilization in the hepatic tissue. This 
process then restores normoglycemia and at the same time inhibiting insulin action 
(Quesada et al., 2008). 
 
In the event that there is a disruption in the coordinated secretion of insulin and 
glucagon, it may lead to lasting pathological effects, including the development of 
type1 diabetes (T1DM) and type2 diabetes (T2DM). Both T1DM and T2DM are 
characterized by gradual failure and destruction of the β-cells. T2DM develops via a 
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complex interplay between genetics and environmental factors such as exposure to 
toxins, diet and alcohol consumption (Cnop et al., 2005). T1DM is characterized by 
an auto-immune assault, which occurs with the invasion of the islets by mononuclear 
cells and induction of intra-islet inflammation and cell apoptosis (Knip et al., 2005). 
Development of T1DM can also be facilitated by exposure to chemicals. Chemical 
substances such as alloxan and streptozotocin are often administered to selectively 
eradicate β cells and induce T1DM. The two chemical substances eradicate β cells by 
inducing oxidative stress and damage by disrupting pancreatic ion transport and 
calcium levels (Szkudelski, 2001).  
 
The major source of blood glucose is dietary carbohydrates such as starch, which are 
hydrolyzed by α-glucosidases and pancreatic α-amylase, so as to be absorbed by the 
small intestine. Inhibitors of the enzymes could retard the uptake of dietary 
carbohydrates, which suppress postprandial hyperglycaemia. Alpha-glucosidase 
inhibitors such as acarbose, miglitol, and voglibose are known to minimize 
postprandial hyperglycemia primarily by interfering with the activity of carbohydrate-
digesting enzymes and decrease glucose absorption (Maurus et al., 2005). 
 
Hypoxis hemerocallidea (HH) is one of the most commonly used medicinal plants in 
South Africa (Nair et al., 2007). It is used for the treatment of numerous ailments 
which include urinary tract infections, heart disease, infertility and anxiety (Brown et 
al., 2008). Due to its usefulness in  traditional medicine, Hypoxis hemerocallidea has 
attracted a lot of interest in scientific studies (Nair et al., 2007). Hypoxis extracts 
contain phytosterols which are thought to be the main pharmacological ingredient 
responsible for  its anti-lipidemic, anti-diabetic and anti-inflammatory properties 
(Boukes et al., 2008). An aqueous extract of Hypoxis hemerocallidea was found to 
exhibit a significant reduction in the blood glucose levels of fasted normal and 
Streptozotocin (STZ) induced diabetic rats (Mahomed & Ojewole, 2003). It is 
thought that the blood glucose lowering effect observed is due to the presence of 
phytosterols and/or sterolin. The mechanism of the blood glucose lowering action is 
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still not well understood. Ojewole (2006) in a study in which an aqueous extracts of 
Hypoxis hemerocallidea were orally administered found anti-diabetic effects starting 
at 100 mg/kg in both normoglycaemic and hypoglycaemic rats.  
 
1.1 The purpose of the study 
 
The plant Hypoxis hemerocallidea, also known as the African potato, is commonly 
used as a traditional medicine to treat diabetes in South Africa. The mechanism by 
which it lowers blood glucose levels is not known. The purpose of this study is thus 
to explore some of the hypoglycemic effects of this plant. 
 
1.1.1 Specific objectives 
 
 To determine the toxicity of Hypoxis hemerocallidea  and glucose on 
pancreatic RIN-5 F cell viability  
 To determine whether Hypoxis hemerocallidea can increase insulin secretion 
from the pancreatic RIN-5 F cells. 
 To determine whether Hypoxis hemerocallidea can inhibit the activity of α-
amylase and α -glucosidase. 
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Chapter II 
 
2 Literature review 
 
The normal range of glucose in the plasma is regulated between 3.5-8.0 mM (Arciero 
et al., 1999). The level of the sugar in the blood outside the normal range may be 
indicative of a medical condition. A persistently high level in blood glucose is 
referred to as hyperglycemia and low glucose levels are referred to as hypoglycemia 
(Colberg & Colberg, 2009; Lee et al., 2005). Glucose levels are usually lowest in the 
morning before the first meal of the day and rise after meals for an hour or two by a 
few millimolar (Colberg & Colberg, 2009; Reddy, 2012).  Glucose transported from 
the intestines or liver to the body cells is made available for uptake by absorption 
cells and metabolism (Reddy, 2012).  
 
Two hormones secreted from the pancreas are mainly responsible for blood glucose 
regulation, insulin and glucagon. Ingestion of carbohydrate elicits a rapid rise in 
insulin concentration and a reduction in glucagon concentration. The increase in 
insulin concentrations happen before a rise in the blood glucose concentration and is 
thought to be mediated largely by hormonal signals arising in the digestive system 
(Aronoff et al., 2004; Kuznetsov, 1978). Glucagon is considered as a hyperglycemic 
hormone which work on the liver to elevate hepatic glucose production when blood 
glucose levels drop.   
 
2.1  The Pancreas and blood glucose level control 
 
The pancreas is a glandular organ in the upper part of the abdomen, but serves as two 
glands in one, a digestive exocrine gland and a hormone-producing endocrine gland. 
Working as an exocrine gland, the pancreas secretes enzymes to digest the lipids, 
proteins and carbohydrates in food (Olubummo, 2010). It weighs between 70 g and 
110 g (Gromada et al., 2007; Nobukawa, 2007). The pancreas is attached to the 
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duodenum, the first part of the small intestine via the common pancreatic bile duct. 
The gland is also extended towards the spleen (Figure 2.1.), 
 
 
                     Figure  2.1.  Diagram showing the front view of the pancreas 
                     (From Nobukawa, 2007). 
 
 
The Langerhans islets (Figure 2.2.) consist of insulin releasing β-cells (65-90 %) 
forming the core of the islet, glucagon-releasing alpha-cells (15-20 %) (Zhou et al., 
2011),   pancreatic polypeptide cells producing PP-cells (1 %) and somatostatin-
producing delta-cells (3-10 %) (Elayat et al., 1995). β-cells, which couple nutrients 
metabolism with electrical activity to modulate the produce and release of insulin, 
have been studied most frequently. The islets of Langerhans play an important role in 
glucose metabolism and organize of blood glucose concentration (Jo et al., 2007). 
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Figure  2.2. Diagram showing the schematic representation of  islets of Langerhans 
embedded in the exocrine parenchyma (From Jo et al., 2007). 
 
2.1.1 Pancreatic hormones 
 
 Insulin 2.1.1.1
 
The effective action of insulin is to decrease blood glucose level in response to 
elevate blood glucose after a meal. β- cells can respond quickly to spikes in blood 
glucose levels by excreting some of its stored insulin while simultaneously generating 
more of the hormone (Wilcox, 2005).  
 
2.1.1.1.1 Insulin structure 
 
The structure of human insulin, as shown in Figure 2.3, consists of 51 amino acids 
forming two polypeptide chains (A and B) (Lotfy, 2012). The smaller A-chain 
consists of 21 amino acids while the B-chain consists of 30 amino acids. The two 
chains are attached by two disulphide links between cysteine amino acids. Similar 
disulphide links are found between cysteine amino acids within the A-chain. The 
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purpose of these disulphide links is to give the insulin molecule its three-dimensional 
structure which guarantees the precise physiological function of insulin (Weise et al., 
2009). 
  
 
Figure  2.3. Diagram showing the structure of human insulin A-chain and B-chain  
(From Lotfy, 2012). 
 
 
2.1.1.1.2 Insulin synthesis 
 
The two polypeptide chains, A and B, are not created as a single polypeptide chain 
but are formed by proteolytic processing of a bigger precursor, proinsulin (Steiner, 
2004). Transcription of the insulin gene results in a mRNA which is translated in the 
ribosome to produce a pre-proinsulin molecule. Removal of its signal peptide during 
insertion into the ER generates proinsulin. This molecule then undergoes chain 
folding and disulphide bond formation, to form an enclosed microvesicle which is 
transported to the Golgi apparatus where it is packaged into storage granules 
(Wicksteed et al., 2001). The proinsulin in the Golgi apparatus undergoes proteolysis 
to form the mature insulin. Insulin and free C peptide, packaged in the Golgi 
apparatus into secretory granules, accumulate in the cytoplasm (Xu et al., 2003). 
These secretory granules include mainly mature insulin (and C peptide) with minor 
quantity of unconverted proinsulin (Wicksteed et al., 2001; Wilcox, 2005).  
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The prime signal in insulin synthesis by β-cells is the blood glucose concentration. 
Hypoglycemia, (2-4 mM glucose), reduces the synthesis of proinsulin, while blood 
glucose concentration of 4-6 mM enhances the synthesis of proinsulin (Steiner et al., 
2009; Brandenburg, 2008). 
 
 
Figure  2.4. Diagram showing the conversion of proinsulin to signal peptide, insulin,C-
peptide, and four basic amino acids and four basic amino acids (From Lotfy, 2012). 
 
 
2.1.1.1.3 Insulin secretion  
 
When the beta cell is appropriately stimulated, insulin is secreted from the cell by 
exocytosis. C peptide is also secreted into the blood but has no biological activity. 
Insulin secretion can be divided into two phases; the first phase of insulin releases the 
KATP channel dependent insulin secretion (Figure2.5). In humans the glucose is taken 
up into b-cell via glucose transporter one (GLUT1) but in mice by glucose transporter 
two (GLUT2) (Hiriart and Aguilar-Bryan, 2008). Glucose is then metabolised by 
glycolysis and the tricarboxylic acid (TCA) cycle (Herman and Kahn, 2006). Both 
pathways provide substrates (FADH2 and NADH) for the respiratory chain within 
mitochondria to produce ATP. ATP is moved into the cytoplasm, where it binds to 
the Kir6.2 subunit of the KATP – channel (Klingenberg, 2008). The binding of ATP 
causes channel closure, resulting in the depolarisation of the plasma membrane. The 
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depolarisation triggers the opening of the L-type voltage-gated Ca
+
 channels, which 
leads to the influx of Ca
2+
 ions. Calcium triggers the exocytosis of insulin secretory 
vesicles and results in the release of insulin from beta cells (Straub and Sharp, 2002). 
As Ca
+
 uptake and insulin release are dependent on potassium channel closure by 
ATP, this corridor is called the KATP channel dependent insulin secretion pathway.   
 
 
 
Figure  2.5. Diagram showing the glucose stimulated first-phase insulin release the beta cells 
(From Maechler &Wollheim, 2000). 
. 
 
The second phase of insulin secretion is called KATP -channel independent insulin 
secretion, as insulin secretion occurs despite the potassium channel being open or 
otherwise dysfunctional (Tengholm and Gylfe, 2009). The second phase involves 
augmented insulin release in response to elevated intracellular calcium levels. This 
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mechanisms are still unknown but are thought to involve changes in actions and 
concentrations of cAMP, phospholipase C and plasma membrane phosphoinositides 
(Straub and Sharp, 2002; Tengholm and Gylfe, 2009). Poorly defined metabolic 
coupling pathways such as generation of mitochondrial NADH, malonyl-CoA and 
cytosolic long chain-CoA esters are also required (Prentki et al., 1997). 
 
 Glucagon 2.1.1.2
 
Glucagon is a polypeptide hormone consisting of a single polypeptide containing 29 
amino acids. It is secreted by the alpha cells on the islets of Langerhans.The cells 
surround a core of insulin secreting beta cells (see Figure 2.2), reflecting a close 
relationship between the hormones insulin and glucagon. Its function is to maintain 
and increase blood glucose levels when needed. This is achieved by stimulating 
glycogenolysis in the liver, promoting gluconeogenesis and by decreasing glucose 
utilisation by the liver, so glucose can be secreted into the bloodstream (Nonogaki, 
2000).  
 
2.1.1.2.1 The interaction between insulin and glucagon 
 
Insulin and glucagon have antagonistic actions on substrate fluctuations, which are 
controlled by the insulin-glucagon ratio. The normal molar ratio is 2:1. It is converted 
to 1:2 when there is a demand for mobilization of endogenous substrates (Adkins-
Marshall et al., 1990). A decrease in insulin release and the increase in glucagon 
release can lead to glycogenolysis and gluconeogenesis in the liver and lipolysis in 
adipose tissue. After a meal, the insulin-glucagon ratio is elevated to about 10:1, 
mainly due to enhanced insulin release. This leads to activation of glucose uptake 
associated with  glucose oxidation and conversion of glucose to glycogen in either 
liver or muscle ( Lotfy, 2012). The pancreatic endocrine action is controlled through 
many factors including glucose. This control involves the parasympathetic nervous 
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system that enhances insulin and glucagon release, while the sympathetic pathway 
enhances glucagon uptake but reduces insulin release (Nonogaki, 2000). 
 
  Somatostatin 2.1.1.3
 
Pancreatic somatostatin is a neuropeptide consisting of 14 amino acids (SS14) 
(Figure 2.6). Somatostatin is manufactured in the form of prosomatostatin by δ-cells 
of islets of Langerhans, but is also synthesized by intestinal cells. Somatostatin 
(SS14) strongly decreases the secretion of glucagon, insulin and pancreatic 
polypeptide (Muroyama et al., 2004). Somatostatin secretion is encouraged by insulin 
when blood glucose levels are high. Somatostatin inhibits insulin synthesis and 
secretion, thus insulin can prevent its own release by stimulating somatostatin 
secretion (Lotfy, 2012). 
 
Generally, it appears that there is a negative feedback relationship of somatostatin 
with either glucagon or insulin (Muroyama et al., 2004). Somatostatin may be an 
additional treatment of diabetes mellitus through its suppressing effect on glucagon 
release (Muroyama et al., 2004). 
 
 
Figure  2.6. Diagram showing the structural features of somatostatin 
(From Conlon et al., 1988). 
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 Pancreatic polypeptide (PP) 2.1.1.4
 
Pancreatic polypeptide (PP) is a peptide consisting of 36 amino acids secreted and 
produced by PP cells of the pancreas which are primarily located in the islets of 
Langerhans, which is part of a family of peptides that also includes neuropeptide Y 
(NPY) and peptide YY (Lotfy, 2012). The essential function of PP is to reduce the 
release of pancreatic bicarbonate and proteins (Clark et al., 1984; Tatemoto et al., 
1982). After a meal, the secretion of PP is stimulated by the decrease in blood 
glucose level (Lotfy, 2012). The PP release is stimulated by the vagal cholinergic 
reflex. Accordingly, PP may induce vagal stimulation of the pancreas and many 
organs in the gut. The PP secretion after a meal leads to reduction of food ingestion 
via decreasing the rate of stomach-emptying (Lotfy, 2012). 
 
2.2 Diabetes Mellitus (DM) 
 
Diabetes Mellitus is one of the pancreatic diseases defined as a chronic disease that 
occurs when the pancreas does not produce sufficient amount of insulin, or when the 
body does not effectively use the insulin it produces (i.e. when the cells become 
resistant to insulin, insulin resistance). Insulin mresistance (IR) may occur at the level 
of the insulin receptor or at the level of downstream signalling (Wilcox, 2005). 
Hyperglycemia is a common sign of uncontrolled diabetes and over time leads to 
serious damage to many of the body's systems, especially the nerves and blood 
vessels (Sugihara et al., 2008).  
 
Diabetic prevalence for all age-groups across the world has been found to be 2.8 % in 
2000 and an estimated to increase to 4.4 % in 2030 (Wild et al., 2004). This is further 
supported by a study finding which speculate that the total number of people with 
diabetes is projected to rise from 171 million in 2000 to 366 million in 2030 
(Deshpande et al., 2008). Men have a higher diabetic prevalence compared to 
women. There are however more women with diabetes than there are men (Wild et 
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al., 2004). In 1980, the World Health Organisation (WHO 2003) classified diabetes 
into type 1 diabetes mellitus (T1DM), an auto-immune disease resulting in the 
destruction of pancreatic β-cells and type 2 diabetes mellitus (T2DM). A strong 
association exists with obesity occurs as a result of failing pancreatic β-cell function, 
responsible for the production of insulin, often alongside insulin resistance.  
 
Butler et al (2003) predicted that a 50% decrease in β-cell function in the presence of 
IR may causes hyperglycaemia. When hyperglyceamia develops, glucose itself leads 
to loss of glucose stimulate-insulin release and impaired glucose utilisation (glucose 
toxicity), which results in an exacerbation of the disease. 
 
Persistent high blood glucose levels could result in the glycosylation of proteins 
which can lead to the irreversible damage as present in diabetes, of tiny blood vessels 
and nerve endings especially in the areas of from the heart, retina and renal 
glomerulus (Deshpande et al., 2008). Macrovascular complications which affect the 
larger blood vessels in the body are common among T2DM patients. These patients 
are more likely to suffer from hypertension and coronary heart diseases (CHD) 
including, atherosclerosis and thrombosis. Around 75 % of macrovascular diabetic 
mortality is due to coronary heart disease (Deshpande et al., 2008). 
 
2.3 Carbohydrate digestion 
 
Carbohydrates are organic compounds, including starches and sugars that serve as a 
major energy source for the body (Huber et al., 2005; Zhang et al., 2010). 
Carbohydrate digestion starts in the oral cavity with salivary amylase and then 
continues in other parts of the gastrointestinal tract, particularly in the small intestines 
(Roberfroid, 2004;  Huber et al., 2005). 
 
Most of the digestion enzymes are hydrolases which are secreted by the salivary 
glands and gastric glands. The digestive enzymes act similar to the lysosomal 
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enzymes, but at different pH optima (Thornhill et al., 2008). Lysosomal enzymes are 
generally active at acidic pH while the digestive enzymes, except pepsins, have their 
activity optima at a pH of 6.5 to 7.5. Many digestive enzymes have trivial, but 
functional names, such as trypsin and pepsin which were used before the systematic 
terminologies were developed. Table 2.1 shows the sources, activators, substrates, 
actions and end products of the enzymes of digestion (Deguara et al., 2003; Gawlicka 
et al., 2000).  
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Table  2.1. The sources, activators, substrates, actions and end products of the enzymes of digestion reproduced from (Arthur & Gruner, 
2007). 
Source 
 
Enzyme Activator Substrate Action Products 
Salivary  
glands  
Salivary  
α-amylase  
(ptyalin)  
Cl-  
 
Starch   Hydrolyzes 
1:4α  linkages 
α-Limit dextrins,  
maltoriose, and  
maltose  
Lingual 
Glands 
Lingual lipase 
 
 Triglycerides  Fatty acids and 
1,2 diacylgliserols 
Stomach Pepsins 
pepsinogens  
 
HCl Proteins and 
polypeptides 
Cleave peptide bonds adjacent to aromatic 
amino acids 
Proteoses, peptons and 
polypeptides   
Gasrtic lipase  Triglyserides Lipolysis   Fatty acids and glycerol 
Pancreas  
 
 
 
 
 
Endopptidases 
Trypsin 
(Trypsinogen)   
Enterokinase 
and trypsin 
Proteins and 
polypeptides 
Cleaves peptide bonds adjacent to arginine or 
lysine 
Polypeptides and amino 
acids 
Chymotrypsins 
(chymotrypsinoge
ns) 
Trypsin Proteins and 
polypeptides 
Cleaves peptide bonds adjacent to arginine or 
lysine 
Polypeptides and amino 
acids 
Carboxypeptidase 
A   
(procarboxypeptid
ase A)              
Trypsin Proteins and 
polypeptides 
Cleaves carboxyterminal 
amino acids that have aromatic or bramched  
aliphatic side chains 
Polypeptides and amino 
acids 
Carboxypeptidase
B  
(procarboxypeptid
ase B)              
 
Trypsin Proteins and 
polypeptides 
Cleaves carboxyterminal 
amino acids that have basic side chains 
Polypeptides and amino 
acids 
 
 
 
 
Colipase 
(procolipase)   
Trypsin Fat droplets   Facilitates exposure of active site of pancreatic 
lipase 
 
Pancreatic lipase    Triglycerides   Lipolysis Monoglycerides and fatty 
acids 
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 Cholesteryl ester  
Hydrolase 
 Cholesteryl esters  Cholesterol and  
fatty acids 
Pancreatic α-
amylase 
CL- Starch Hydrolyzes 
1:4α  
linkages 
α-Limit dextrins, 
maltoriose, and maltose 
Phospholipase A2 
(Prophospholipase 
A2) 
Trypsin Phospholipids  Fatty acids,  
Lysopholipids 
Intestinal 
mucosa 
 
 
 
 
 
Dipeptidase  Dipeptides  Amino acids  
 
Maltase  Maltose, 
maltotriose 
 Glucose 
Lactase 
 
 Lactose  Galactose and glucose 
Sucrase  Sucrose  Fructose and glucose 
α-Limited 
dextrinase 
 Α-Limit dextrins  Glucose 
Cytoplas
m  
of 
mucosal  
Various peptidases    Di, tri, and   
tetrapeptides 
 Amino acids 
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2.4 The digestion enzymes  
 
The digestive enzymes α- amylase and α-glucosidase assist in the breakdown of 
complex carbohydrates   (oligosaccharides and starch) in the digestive tract, forming 
simple sugars such as glucose, sucrose and maltose (Dong et al., 2012). One of the 
important treatments for high postprandial glucose levels is to delay the absorption of 
glucose by using using inhibitors of the hydrolysing enzymes α- amylase and α-
glucosidase. 
 
2.4.1 Alpha-amylase 
 
Alpha-amylase (EC 3.2.1.1) is a digestive enzyme that hydrolyses alpha -1, 4 bonds 
of large polysaccharides such as starch and glycogen by converting them into smaller 
products which are glucose and maltose. Alpha-amylase is widespread among living 
organisms (Maurus et al., 2005). The primary sequences of α-amylases in different 
species show poor serial homology, although the three-dimensional structures of the 
enzymes are found to be conserved in organisms ranging from microbial to 
mammalian (Janeček et al., 2014; Kandra, 2003). Striking amongst the structural 
similarities is the existence of three domains in the enzyme structure. Domain A 
consists of an α/β keg and contains the active site, domain B protrudes from the side 
of domain A and consist of the calcium binding site, and domain C forms a 
structurally independent antiparallel β-barrel (Maurus et al., 2005; Kandra, 2003). 
The identical structural features of human pancreatic α-amylase are shown in Figure 
2.7. 
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Figure  2.7. Diagram showing the structural features of human pancreatic  α-amylase 
(From Maurus et al., 2005). 
 
 
Alpha-amylase begins the process of starch digestion. It takes starch chains and 
breaks them into short saccharides with two or three glucose units. Two similar types 
of amylase are made in the human body. Salivary amylase is synthesized in the 
serous acinar cells of the saliva glands. It is then stored in secretory granules inside 
the cells and then released from the salivary cells, especially with an increase in 
response to taste or chewing motions of the jaw (Maurus et al., 2005). It starts the 
breakdown of starch into smaller pieces when food is chewed. The second amylase 
and pancreatic amylase, are secreted by the pancreas, completes the digestion of 
carbohydrates. The saccharides are broken into individual glucose units by a 
collection of enzymes that are tethered to the walls of the intestine (Yilmazer-Musa et 
al., 2012; Lordan et al., 2013). 
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2.4.2 Alpha-Glucosidases Enzyme 
 
Alpha-glucosidase is an enzyme that breaks down starch and disaccharides to glucose 
and maltose (Lu & Sharkey, 2006), and is also called alpha-1, 4-glucosidase EC 
3.2.1.20 (Figure 2.8) (Woo & Wynne,  2011) which is located in the brush border of 
the small intestine and acts upon 1,4-alpha bonds (Sun & Henson, 1990). 
 
Alpha-Glucosidase is involved in carbohydrate breakdown. It plays a crucial role in 
diabetes and also in viral infections and cancer. Alpha-glucosidase delays the 
hydrolysis of carbohydrates and alleviate postprandial hyperglycemia (Hemmerich, 
2001; Kumar et al., 2011) 
 
Figure  2.8. Diagram showing the alpha-glucosidase chemical structural 
(From Woo & Wynne,  2011). 
 
2.5 Glucose metabolism 
 
Once glucose has been transported into the beta cells it enters glycolysis in the 
cytoplasm where it is metabolised to pyruvate (Herman and Kahn, 2006). Pyruvate 
enters mitochondrial matrix where it acts as a substrate for pyruvate carboxylase, 
which converts pyruvate to oxaloacetate, and for pyruvate dehydrogenase, which 
converts it to acetyl-CoA (Herman and Kahn, 2006). Both oxaloacetate and acetyl-
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CoA are substrates for the TCA cycle that provides NADH and FADH2 for the 
mitochondrial respiratory chain (Wollheim and Maechler, 2002). 
 
2.6 Mitochondrial function in beta cells 
  
Mitochondrion is double-membrane organelles with multiple essential cellular 
functions. The main function of this to produce energy in the form of ATP from 
acetyl CoA derived from, fats, carbohydrates and proteins (Dimmer et al., 2002). 
ATP is the universal currency of energy in the cell. It is an energy-rich molecule 
because it contains two phosphoanhydride bonds. Energy is released when these 
bonds are broken. ATP can be synthesized from adenosine diphosphate (ADP) by 
two processes, which are substrate-level phosphorylation and oxidative 
phosphorylation. Substrate level phosphorylation is the process by which ATP is 
formed from the direct phosphorylation of ADP (Klingenberg, 2008).  All of these 
processes related to cell energy production and utility, therefore, mitochondrion is the 
power plant of cells. The primary or secondary alterations in mitochondria related 
signalling pathways could be explained multiplicity of organelle functions and va-
riability in the pathophysiology (Dimmer et al., 2002; Klingenberg, 2008). Around 
90% of cellular ATP is generated by oxidative phosphorylation, a process via which 
ATP is formed as electrons are transferred from nicotinamide adenine dinucleotide 
(NADH) and flavin adenine dinucleotide (FADH2) to molecular oxygen, by a series 
of electron carriers that make up the electron transport chain (ETC) (Wollheim and 
Maechler, 2002). Carbohydrates are converted to pyruvate through glycolysis, which 
is held in the cytosol. Pyruvate is subsequently actively transported across the inner 
mitochondrial membrane, and into the mitochondrial matrix where it is oxidised and 
changed it to acetyl CoA by pyruvate dehydrogenase. It is well established that 
mitochondrial function is required for normal glucose-stimulated insulin secretion 
from pancreatic b cells. In addition, maternally inherited deformities in mitochondrial 
DNA that disturb mitochondrial function are known to cause an insulin-deficient 
form of diabetes like T1DM (Lowell and Shulman, 2005).  
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2.7  Medicinal plants used to control blood glucose level 
 
Despite considerable progress in the treatment of diabetes by oral hypoglycemic 
agents, the search for newer drugs continues because the existing synthetic drugs 
have several limitations. Traditional treatments are prescribed by practitioners of 
alternative medicine or sometimes taken by patients as supplements to conventional 
therapy. Hypoglycemic action of some traditional treatments has been confirmed in 
animal models and T2DM (Arumugam et al., 2013). 
 
Herbal medicine plants having anti diabetic properties could be a useful source for the 
development of safer and effective oral hypoglycemic products. More than 400 
traditional plants are used in the treatment of diabetes mellitus. The herbal drugs with 
antidiabetic activity are yet to be commercially formulated as modern medications; 
moreover, they have been acclaimed for their therapeutic medicinal properties in the 
traditional systems (Arumugam et al., 2013). Only a small number of these have 
received the scientific and medical evaluation to estimate their efficacy. Traditional 
treatments may provide valuable clues for the development of new oral hypoglycemic 
agents and simple dietary adjuncts (Arumugam et al., 2013). Table 2.2 shows the 
most important medicinal plants used for the control of blood glucose level 
(Kavishankar, 2011). 
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Table  2.2. Most important medicinal plants having antidiabetic activity. Reproduced from  
(Arumugam et al., 2013). 
 
Plant name  
 
Family Parts 
used 
Type of extract Activity 
Alangiumlamarckii Alangiaceae Leaves Alcoholic Antidiabetic 
Albiziaodoratissima Mimosaceae Bark Methanol Antidiabetic 
Axonopuscompressus Poaceae Leaves Methanol Antidiabetic 
Berberis vulgaris Berberidaceae Root  Aqueous Hypoglycaemic 
Brassssicajuncea Cruciferae Seed Aqueous Hypoglycemic 
Caesalpiniadigyna Fabaceae Root Methanol Antidiabetic 
Catharanthusroseus Apocynaceae Leaf Methanol Hypoglycemic 
Centauriumerythrea Gentianaceae Leaf Aqueous Antidiabetic 
Chaenomelessinensis Rosaceae Fruits ethyl acetate Antidiabetic 
Cocosnucifera Arecaceae Leaf  hydro-methanol Antihyperglycemic 
Costusspeciosus Costaceae rhizome hexane Antidiabetic 
Cyclocaryapaliurus Cyclocaryaceae Bark Aqueous, PE, 
chloroform, ethyl 
acetate &n-
butanol 
Hypoglycemic 
Dilleniaindica Dilleniaceae Leaves Methanolic Antidiabetic 
Embeliaribes Myrsinaceae Berries Hexane Antidiabetic 
Hybanthusenneaspermus Violaceae Whole 
plant 
Alcholic 
 
Antidiabetic 
Lippanodiflora Verbenaceae Whole 
plant 
Methanol Antidiabetic and 
Hypolipidemic 
Lithocarpuspolystachyus Fagaceae Leaves Ethanol & 
Aqueous 
Hypoglycemic 
Marrubiumvulgare Lamiaceae Aerial 
part 
Methanol Hyperglycmia 
And dyslipidemia 
Ocimum sanctum  Lamiaceae Aerial part HydroalcholicAntid
iabetic 
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Opuntiastreptacantha Cactaceae Leaves Ethanol Antihyperglycemia 
Psidiumguajava Myrtaceae Fruits Ethanol Antihyperglycemic 
Semecarpusanacardium Anacardiaceae nut Milk Antidiabetic 
Prosopisglandulosa Fabaceae Whole 
plant 
Gelatine/Jelly Antidiabetic 
Ophiopogonjaponicus Asparagaceae Root Ethanol Hypoglycemic 
Setariaitalica Poaceae Seed Aqueous  Antihyperglycemic 
Solanumtorvum Solanaceae Fruits Methanol Antihyperglycemic 
Cassia auriculata Caesalpiniacae Leaves Aqueous Antihyperglycemic 
Zygophyllum album Zygophyllaceae Whole 
plant 
Ethanol Antidiabetic 
Vitexnegundo Lamiaceae Leaves Methanol Antihyperglycemic 
Viscumschimperi Viscaceae aerial 
parts 
Methanolic Antihyperglycemic
&Hypolipidaemic 
Symplocoscochinchinensis Symplocaceae Leaves Hexane Antidiabetic 
Enicostemmalittorale Gentianaceae Whole 
plant 
aqueous Antidiabetic 
Vacciniumarctostaphylos Ericaceae Fruit Ethanolic antidiabetic 
Solanumxanthocarpum Solanaceae Leaves Aqueous and 
Methanol 
Antihyperglycemic 
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2.8 Hypoxis hemerocallidea (HH) 
 
Hypoxis hemerocallidea (HH) is one of southern Africa’s most important and popular 
medicinal plants (Nicoletti et al., 1992). HH has a long history of traditional use for a 
diversity of ailments and more recently has been the subject of several scientific 
studies. In many parts of Africa the corms of this attractive yellow flowered herb 
have been used in the treatment of urinary tract diseases, prostate hypertrophy and 
cancer (Mahomed & Ojewole, 2003). HH is geophytic and overcome winter 
conditions in the form of an underground rootstock called a corm. It also has 
adventitious roots attached to the corms that are thick, fleshy and which arise from 
the base of young corms. The flowering stems are unbranched, with 2-12 flowers per 
stalk. Flowers are symmetrical with 6 petals, which are bright yellow, giving the plant 
its common name Yellow Stars, shown in Figure 2.9 (Nair, 2006; Nair & Kanfer, 
2006). 
 
 
 
 
Figure  2.9. Diagram showing the photograph of a Young Corm of HH,  Flowers are 
symmetrical with 6 petals, which are bright yellow, giving the plant its common name 
Yellow Stars (From Nair, 2006). 
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The corms of these plants are graded on size. The small (200 g) corms are generally 
from one year old seedlings and the medium corms (450 g) are at least three years 
old, whereas the large corms (800 g) are older(Nair, 2006). The fleshy corms of HH 
are yellow in colour on the inside (Figure 2.10), but soon turn to dark brown due to 
oxidation, when exposed to air (Nair, 2006). The uses of this plant can be attributed 
to a few of the medicinal compounds found in the plant of which hypoxoside, 
sitosterol, and its aglycone derivative rooperol are the most well-known compounds 
(Street & Prinsloo, 2012). 
 
 
Figure  2.10. Diagram showing the photograph of the Transection of a Corm of HH      
    (From Nair, 2006). 
 
2.8.1 Vernacular names 
 
The family name of Hypoxis hemerocallidea is Hypoxidaceae. 
The most common names for HH are Star Lily, Yellow Stars, Afrika-patat, Sterretjie, 
African Potato, Inkomfe and Ilabatheka (Street and Prinsloo, 2012).  
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2.8.2 Geographical distribution  
 
In South Africa, the genus is distributed in five provinces, namely, Eastern Cape, 
KwaZulu-Natal, Limpopo, Mpumalanga and Gauteng but it is also found in Lesotho, 
Swaziland, Mozambique, and Zimbabwe (Singh, 2007). There are reports of its 
existence in various other countries including Madagascar, New Zealand, Malawi, 
America, Mauritius  and other Central Africa countries (Mogatle, 2008). 
 
2.8.3 Botanical classification 
 
The particular nomenclature for Hypoxis depends on leaf figurers, leaf venation, 
flower figurers and inflorescence (Singh, 2007). In Africa there are 30 types of 
Hypoxis. Most of these kinds tend to become common endemic to southern Africa. 
Hypoxia hemerocallidea found in the Eastern Cape region of South Africa (Mogatle, 
2008). Most of the species are arranged under one of names are presented below: 
 
• Hypoxis angustifolia var buchananii. 
• Hypoxis argenta var sericea. 
• Hypoxia colchicifolia. 
• Hypoxia floccose. 
• Hypoxis hemerocallidea. 
• Hypoxia longifolia. 
• Hypoxis obtuse. 
• Hypoxia ridicule. 
• Hypoxis ridigula var pilosissima. 
 
2.8.4 Traditional forms  
 
Hypoxis hemerocallidea have been used traditionally for a wide range of purposes by 
different tribes of Southern Africa. They have been used by the Zulu tribe as an 
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internal parasiticide, purgative and to treat delirium. The Maniyaka tribe applied the 
ash to treat wounds, whereas the Karanga tribe used it as a remedy for bilious 
vomiting, anorexia, abdominal pain and fever (Botha & Penrith, 2008). 
 
The corm of the plant has been used in folk medicine to treat a variety of diseases 
which include the common cold, flu, hypertension, adult-onset diabetes, psoriasis, 
urinary tract infections, testicular tumours and prostate hypertrophy. HH is used to 
build up the immune system of patients suffering from HIV/AIDS, anticancer, 
antidiabetic, antimicrobial, antioxidant, and anti-inflammatory treatment (Mogatle, 
2008). Table 2.3 shows the most important traditional uses of HH.  
 
Table  2.3. Traditional uses of HH reproduced from (Mogatle, 2008). 
 
Reported Use 
 
Part  
of plant 
           Preparation Area Reference 
Diabetes Corms Fresh corms boiled and 
taken orally 
Eastern Cape 
South Africa 
(Erasto et al., 
2005) 
Prostate 
Hypertrophy 
 
NS* 
 
NS* Maputo 
Mozambique 
(Mills et al., 
2005) 
Urinary or 
venereal 
diseases 
NS* NS* KwaZulu 
Natal 
South Africa 
(Louw et al., 
2002) 
Cancer 
 
Corms Pulverised corms are boiled  
And taken orally 
Eastern Cape 
Southern 
Africa 
(Koduru et al., 
2007) 
Wound 
management 
Leaves 
corms 
Dry powder sprinkled on 
wounds 
Fresh or dried material 
extracted and used as wash 
Eastern Cape 
South Africa 
(Grierson and 
Afolayan, 1999) 
HIV/AIDS 
management 
NS* NS* Johannesburg, 
South Africa 
(Babb et al., 
2007) 
*NS – not state. 
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2.8.5 Aspects of the use, pharmacology and phytochemistry 
 
HH contains many chemical constituents of which hypoxoside, rooperol, and the 
phytosterol, β-sitosterol are the main ones (Muwanga, 2006; Boukes and van de 
Venter 2011; Sathekge, 2011). These chemical agents contribute to the wide array of 
pharmaceutical properties that extracts of HH provides (Owira and Ojewole, 2009). 
  
Hypoxoside is the trivia name for (E)-1, 5 bis (4′-B-D-glucopyranossyloxy-3′-
hydroxyphenyl) pent-1-en-4-yne, a norlignan diglucoside from the rootstock of the 
family Hypoxidaceae. Phytosterols such as 𝛽𝛽-sitosterols is effective against benign 
prostate hypertrophy, and a decoction of the rootstocks is also used as a laxative 
(Mills, Cooper, et al., 2005; Steenkamp, 2003). Rooperol could be acquired by 
treating hypoxoside with a 𝛽𝛽-glucosidase to remove the attached glucose groups. In 
addition to hypoxoside and rooperol the rootstocks also consists of 𝛽𝛽-sitosterols,  
monterpene glycosides, stigmastanols, and stanols (Street & Prinsloo, 2012). The 
chemical analysis of HH showed that the species have various classes of secondary 
metabolites namely saponnins, glycosides,  polyphenols,  steroids and tannins. The 
rootstock of HH has produced three cytokinins identified as zeatinriboside, 
zeatinglucoside and zeatin (Street & Prinsloo, 2012). 
 
2.8.6  Toxicity  
 
A lethal dose (LD50) in mice was found to be 1948 ± 57 mg/kg of HH aqueous 
extract after oral administration (Ojewole, 2006). A lower dose (≤ 1600 mg/kg) of 
HH aqueous extracts is safe while relatively higher doses were toxic and/or lethal to 
the mice (Ojewole, 2006). A clinical trial was conducted involving 24 cancer patients 
at Karl Bremer Hospital, Bellville, South Africa (Smit et al., 1995), where the 
toxicity of hypoxoside, which was administered in the form of a hypoxis plant 
extract, was assessed. The patients were given 1200 - 3200 mg standardised hypoxis 
plant extract (50-55% hypoxoside content) /day, in three divided doses. Based on 
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haematological and biochemical tests it was concluded that the dose administrated 
was not toxic (Mogatle, 2008). 
 
2.8.7  Registered Patents 
 
Several patents of Hypoxis, hypoxoside, rooperi and rooperol have been registered in 
the Europe and the USA. A patent registered under the title (method of treating viral 
infections) was registered by Liebenberg (Mogatle, 2008). That related to bulbous of 
the family of hypoxidaceae in preparation of medicament to treat viral infection by 
cutting the rate of reduction of T lymphocytes The patents include methods of 
extraction and preparation of derivatives (Mogatle, 2008). 
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CHAPTER III 
 
3  Materials and methods 
 
3.1 Materials 
 
3.1.1 Chemicals and Equipment  
 
 Lonza group Brighton, UK supply: 3.1.1.1
 
 RPMI (Roswell park-memorial institute) 1640 media (BE12-702F). 
 RPMI1640 phenol Red free media (BE12918F). 
 Glucose (BE02-040E).  
 Trypsin EDTA (BE17-161F). 
 Penicillin-Streptomycin (BE17-161F).  
 L-Phosphate Buffered Saline (PBS) (17-516F). 
 glutamine (BE17-60SE). 
 
  Medical Research Council (MRC) supply:  3.1.1.2
 RIN5F cells passage 18. 
 
 SPL Life sciences supply:  3.1.1.3
 12- and 96-well plates.  
 Tissue culture flasks (25 cm² and 75 cm²).  
 Test tubes (15 ml and 50 ml).  
 Eppendorf vials.  
 Pipettes (2 ml and 10 ml). 
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 Gibco Invitrogen, Karlsruhe supply: 3.1.1.4
 Foetal Bovine Serum (FBS). 
 
  Kimix chemicals supply: 3.1.1.5
 Ethanol. 
 
 Lasec supply: 3.1.1.6
 Whatman’s filter paper number 4 and 1 (240 μm thick).  
 
 Sigma-Aldrich supply:  3.1.1.7
 Triton X-100. 
 Crystal violet (c3886). 
 Rat Insulin ELISA Kit (090B0743) 
 
 Thermo Scientific supply:  3.1.1.8
 M-PER Mammalian Protein Extraction Reagent prod # (78501). 
 BCA Protein Assay Kit (PG205949). 
 
 Merck supply:  3.1.1.9
 25 % Gluteraldehyde. 
 
 Scharlau Scientific supply: 3.1.1.10
 Dimethylsulphoxide (DMSO) SU0155. 
 
 Biovision supply: 3.1.1.11
 α- Amylase Activity Colorimetric Assay Kit (K711-100). 
 α- Glucosidase Activity Colorimetric Assay Kit (K690-100). 
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  Roche supply: 3.1.1.12
 XTT kit [2, 3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide inner salt]. 
 
 Vacuum system: 3.1.1.13
Brock crumbtion, (BS2208). 
 
 Centrifuges: 3.1.1.14
Lasec, Hermle (Z160M). 
 
  Microscopes:  3.1.1.15
Zeiss, Oberkochen, (195-42424 ICM405). 
 
 Plate shaker  3.1.1.16
MINI Rocker, BOECO, 96-well flat bottom. 
 
 Thermo Scientific supply:  3.1.1.17
 96-well ELISA (Enzyme-linked immunosorbant assay). 
 5 % CO2 Cell culture incubator 
 
  Spectrophotometer  3.1.1.18
 Beckman, Model (DU 640). 
 
3.2 Methods 
 
3.2.1 General cell culture procedures 
 
The RIN-5F cell line is a clone derived from the RIN-m rat pancreatic islet. The cells 
produce and secrete insulin as well as L-dopa-decarboxylase, a marker for cells 
 
 
 
 
33 
 
having amine precursor uptake and decarboxylation (APUD) (Bhathena et al., 1982; 
Bhathena et al., 1984).  
 
The cells were maintained in 25 cm² and 75 cm² flasks in RPMI 1640 medium 
containing 0.5 µM of glucose, 100 u/ml penicillin and 100 pg/ml streptomycin and 16 
% foetal bovine serum (FBS). The cells were maintained at 37 °C, 5 % CO2 and 95 % 
humidity. Cells were allowed to grow for 72 hours before the media was removed 
and replaced with fresh growth medium.  
 
3.2.2 Passaging cells 
 
Once the cells culture in flasks reached 70 -80 % confluencey the culture medium 
was aspirated and the cells were washed using 1 ml of PBS. The PBS was aspirated 
and 1 ml of 0.25 % trypsin was added to the flask and incubated at 37 °C until the 
cells began to detach, after a period of 3-5 minutes. The flasks were tapped lightly to 
allow cells to detatch from the surface of the flasks. Equal amounts of medium were 
added to inhibit the action of trypsin. The cell suspension was then centrifuged for 5 
minutes at 2000 rpm. Following this, the supernatant was aspirated and 2 ml of 
culture medium was used to re-suspend the pellet. Every 1 ml of the suspension was 
added to 4 ml of culture medium in tissue culture flasks, then used in experiments or 
incubated again at 37 °C and 5 % CO2. 
 
3.2.3 Cryo-preservation 
 
Cryo-preservation followed the same procedure as mentioned in the section 3.2.2. 
After the cells had been centrifuged it was re-suspended in ―freeze medium‖. Freeze 
medium is composed of 10 % DMSO, 20 % FBS and 70 % culture medium in a ratio 
of 1: 2:7. The cell suspension was then added to a cryo-vial and frozen at - 80 °C. 
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3.2.4 Cell counts  
 
Cryo-preserved cells were thawed and added to 4 ml of culture medium in a 
centrifuge tube and centrifuged for 5 minutes at 2000 rpm. Following this, the 
supernatant was aspirated and the cells were re-suspended in 2 ml culture medium. 
 
Cell proliferation and cell density was determined using a haemocytometer. A ratio of 
1:3 (trypan blue: cell suspension) was used to determine the amount of cells. A 
volume of 10 μl trypan blue was added to 10 μl of the cell suspension in an 
Eppendorf tube.  A 10 μl aliquot of this solution was then placed on each side of the 
slide and counted. Dead cells took up the dye and were therefore stained blue, whilst 
the viable cells did not take up the dye, so they remained clear and were counted. The 
number of cells per ml was determined by the following calculation:  
 
Equation 1  
                                                        
 
The cell suspension was then diluted with medium to give the required cell number 
and was seeded into the appropriate culture plates. 
 
3.3 Plant material 
 
Crushed powder corms of Hypoxis hemerocallidea (HH) (Family: Hypoxidaceae) 
were purchased from Global fusion trading store in Hout Bay – Cape Town, South 
Africa. 
 
3.3.1 Preparation of HH corm aqueous extract 
 
Boiling distilled water (1.5 L) was added to 50 g of HH cruched powder and left at 
room temperature for 3 hours, after which it was filtered through cheese cloth and 
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Whitman’s filter paper number 4 and 1 consecutively. The filtrating process was 
completed using a vacuum system. Liquid nitrogen was used to freeze it quickly and 
the filtrate was freeze dried for 4-5 days. 
 
 The extract obtained was concentrated to dryness under reduced pressure at 30 ± 1 
o
C. The resulting crude extract obtained was freeze-dried, finally giving (8 g) Hypoxis 
hemerocallidea powder (HHP). Without any further purification, aliquot portions of 
the crude extract residue, were weighed and dissolved in RPMI1640 media for use on 
each day of the experiment. 
 
3.4 Experimental techniques 
 
3.4.1 Determination of cell proliferation of RIN-5F cell by crystal violet 
staining 
 
Crystal violet is a method used to determine cell numbers by staining the DNA 
(Skehan et al., 1990). Crystal violet was used to quantify cell number in monolayer 
cultures as a function of the absorbance of dye taken up by the cells. The cell 
numbers were expressed as a percentage of the cells propagated in growth medium.  
The fixed dye measured photometrically after solubilisation, correlates with the 
nuclear DNA content and thus with cell number (Basu et al., 1968). Crystal violet 
belongs to a class of intensely colored organic compounds called triphenylmethane 
dyes. The chemical structure (Figure 3.1) and color of crystal violet depend on the 
pH, making it a valuable acid−base indicator as well as an excellent dye. The major 
structural form of crystal violet is the monovalent cation that can rapidly permeate the 
cell wall  (Basu et al., 1968). 
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Figure  3.1. Chemical structure of crystal violet (Basu et al., 1968). 
 
Crystal violet stain was prepared by dissolving 2 g of crystal violet in 20 ml of 95 % 
ethyl alcohol and 0.8 g ammonium citrate monohydrate and was dissolved in 80 µl 
deionized water. Subsequently, the two mixtures were added together and filtered as 
crystal violet working solution. 
 
Cell proliferation and cytotoxicity assays can be used for drug screening and 
cytotoxicity tests of chemicals. They are based on different cell functions such as 
enzyme activity,  cell adherence, cell membrane permeability, co-enzyme production, 
ATP production and nucleotide uptake activity (Ishiyama, 1997; Tominaga et al., 
1999). 
 
 The effect of glucose on cell proliferation 3.4.1.1
 
The cells were seeded at approximately 5x10
3
 cells per well in 96-well plates. The 
plates were incubated at 37 
o
C
 
and 5 % CO2 for 24 hours to allow for attachment. The 
medium was discarded. Untreated cells served as control, and the other cells were 
treated with different concentrations of glucose (5, 10, 20, 37.5, 50, 55, 74 and 92.3 
mM) for 1, 3, 6 or 24 hours. 
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 The effect of HH on cell proliferation 3.4.1.2
 
The cells were seeded at approximately 5x10
3
 cells per well in 96-well plates. The 
plates were incubated at 37 
o
C and 5 % CO2 for 24 hours to allow for attachment. The 
medium was discarded. Untreated cells served as controls, and the other cells were 
treated with different concentrations of HH (50, 100, 150, 200 and 500 µl/mol) for 1, 
3, 6 or 24 hours. After the cells were exposed and the medium was discarded from 
each well, 100 µl of gluteraldehyde (1 %) was added, followed by incubation at room 
temperature (RT) for 15 minutes. Next, the gluteraldehyde was removed and crystal 
violet working solution was added to each of the wells and then incubated at room 
temperature for 30 minutes. Thereafter, the plates were immersed in running tap 
water for 15 minutes and then dried by placing on paper towel. The plates were then 
left overnight. 
 
The next day 200 µl (0.2 %) of Triton X-100 were added to each well and incubated 
at room temperature for 30 minutes. Subsequently, 100 ml of the solution in the wells 
were transferred to new 96-well microplates and the absorbance read at 570 nm using 
a 96 wells microplate reader. The experiment was repeated 3 different times. The 
viability was calculated by the formula below (Equation 2): 
 
Equation 2 
                       
                     
                           
       
 
3.4.2 Cell viability assessment by XTT assay (2, 3-bis-(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide) 
 
The XTT cell viability assay was described in 1988 by Scudiero et al. (Scudiero et 
al., 1988) as an effective method to measure cell growth and drug sensitivity in tumor 
cell lines. XTT is a colourless or slightly yellow compound that when reduced 
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becomes brightly orange. This color change is accomplished by breaking apart the 
positively-charged quaternary tetrazole ring (Berridge et al., 2005). The formazan 
product of XTT reduction is soluble and can be used in a real-time assay. XTT is 
thought to be excluded from entering cells by its net negative charge (Berridge et al., 
2005). Considerable evidence suggests that XTT dye reduction occurs at the cell 
surface facilitated by trans-plasma membrane electron transport (Berridge et al., 
2005). Mitochondrial oxidoreductases are thought to contribute substantially to the 
XTT response with their reductants being transferred to the plasma membrane. It has 
been proposed that the XTT assays actually measure the pyridine nucleotide redox 
status of cells (Scudiero et al., 1988; Berridge et al., 2005). 
 
PMS (N-methyl dibenzopyrazine methyl sulfate), an intermediate electron acceptor is 
the activation reagent in the XTT cell viability assay kit. PMS mediates XTT 
reduction by picking up electrons at the cell surface, or at a site in the plasma 
membrane that is readily accessible and forms a reactive intermediate that then 
reduces XTT to its highly pigmented formazan product (Figure 3.2) (Berridge et al., 
2005). 
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Figure  3.2. Cell viability assay XTT (Berridge et al., 2005). 
The XTT assay is a colorimetric assay for the nonradioactive quantification of 
cellular proliferation, viability, and cytotoxicity. Quantification of viable cells in a 
population gives an indication of cell viability. Warm XTT labelling mixture 
(provided in the kit and prepared according to manufacturer’s instructions) was added 
to cell culture wells. The plate was incubated at 37 
o
C, 5 % CO2 and 95% humidity 
for 3-4 hours. Metabolically active cells convert the XTT into insoluble formazan 
crystal that can be directly quantified using a spectrophotometric plate reader. The 
absorbance was measured at 450 nm and results recorded. 
 
Kit contents: 
 XTT labelling reagent (2, 3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide). 
 Electron-coupling reagent. 
To prepare XTT labelling mixture, the XTT labelling reagent was mixed with 
electron-coupling reagent prior to use. 
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  The effect of glucose on cell viability  3.4.2.1
 
The cells were seeded at approximately 5x10
3
 cells per well in 96-well plates. The 
plates were incubated at 37 
o
C and 5 % CO2 for 24 hours to allow for attachment. The 
medium was discarded. Untreated cells served as controls and the other samples were 
treated with different concentrations of glucose (5, 10, 20, 37.5, 50, 55, 74 and 92.3 
mM). The 50µl XTT labelling mixture was added to each well and the plate read at 
405nm at time 0 minute. The plate was incubated for 1 h at 37 °C and 5 % CO2 and 
read again at 405 nm to get the actual data. To obtain the final result the 0 time 
reading was subtracted from the 1hr reading. 
 
 The effect of HH on cell viability  3.4.2.2
 
The cells were seeded at approximately 5x10
3
 cells per well in 96-well plates, and 
plates were incubated at 37 
o
C and 5 % CO2 for 24 hours to allow for attachment. The 
medium was discarded. Untreated cells served as control, and the other cells were 
treated with different concentrations of HH (50, 100, 150, 200 and 500 µl/mol) for 1, 
3, 6 or 24 hours. A volume of 50 µl of XTT labelling mixture was added to each well 
and the plate read at 405 nm at time 0. The plate was then incubated for 1 hour at 37 
°C and 5 % CO2 and read again at 405 nm to get the actual data. The absorbance of 
the samples was determined using a microplate (ELISA) reader. The experiments 
were repeated 3 times. The cell viability was calculated by the formula below 
(Equation 3): 
 
Equation 3 
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3.4.3 Insulin Secretion Assays for RIN5-F cells 
 
Equal numbers of cells were seeded in 12 well tissue culture plates containing phenol 
red free RPMI1640 with 0.5 µM of glucose, supplemented with 340 µL-glutamine 
and 5 % FPS. The cells were incubated at 37 ºC for 24 hours to allow for attachment. 
Cells were washed twice with PBS and exposed to HH (100 µg/ml or 500 µg/ml) 
and/or 2 mM or 50 mM glucose for 30 minutes to stimulate insulin secretion. The 
medium was removed from each well and discarded. The cells were washed twice 
with PBS. Fresh medium containing same treatment of glucose and HH was added to 
each well (2 ml/well). Untreated cells served as controls.  
 
The plates were incubated for 30 minutes and then 1 ml of the supernatant was 
removed, placed in Eppendorf tubes, and stored at -80 °C. The plate were re-
incubated for 90 minutes, then 1ml of supernatant was placed in an  Eppendorf and 
stored at (-80 °C). All samples were performed in triplicate and each experiment was 
repeated three times. Insulin content was determined by an ELISA.  
 
 Determination of insulin secretion by RIN 5F cells 3.4.3.1
 
Insulin was measured in the cell culture supernatants using a commercially available 
kit (RAB0904 Rat Insulin ELISA Kit). This assay employs an antibody specific for 
human insulin coated on a 96-well plate. Standards and samples were pipetted into 
the wells and the insulin present in a sample was bound to the wells by the 
immobilised antibody. The wells were washed and biotinylated anti-human insulin 
antibody was added. After washing away unbound biotinylated antibody, HRP-
conjugated streptavidin was pipetted into the wells. The wells were again washed, a 
TMB substrate solution was added to the wells and colour developed in proportion to 
the amount of insulin bound. The stop solution changed the colour from blue to 
yellow, and the intensity of the colour was measured at 450 nm.  
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 Determination of protein 3.4.3.2
 
3.4.3.2.1 Procedure for lysis of adherent mammalian cells 
 
To determine the protein concentration of each sample the culture medium was 
carefully removed from the adherent cells. The cells were washed once in PBS. A 
volume of 50 µl of M-PER® Reagent was added to each well and the plate was 
shaken gently for 5 minutes. The lysate was collected and transferred into a new 
Eppendorf and centrifuged at 14,000 x g for 8 minutes to pellet the cell debris. The 
supernatant was transferred to new Eppendorf tubes. An aliquot of 25 µl of 
supernatant was transferred to each well to prepare it for the protein determination 
assay. The protein content was measured by the BCA Protein Assay Kit (PG205949) 
according to instructions. 
 
3.4.3.2.2  Protein kit 
 
A volume of 25 µl of each protein standard (25 µg/ml – 2000 µg/ml) and the samples 
were prepared and added to the wells. The working reagent (WR) was prepared by 
mixing 5 ml of Reagent A (500 ml containing sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) and 100 µl of 
reagent B (25 ml containing 4 % cupric sulphate), then 200 µl per well was added. 
The plate was covered and placed in an incubator for 30 minutes at 73 oC.  
Subsequently the absorbance was read at 560 nm in a 96 well plate reader. Each 
sample was analysed in triplicate.  
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3.4.4 Alpha amylase and alpha glucosidase inhibition activity 
 
 Alpha Amylase  3.4.4.1
 
Alpha amylase inhibition of the HH aqueous extract was measured using a 
commercially available Amylase Activity Colorimetric Assay. The assay used 
ethylidene-pNP-G7 as the substrate. Once the substrate had been specifically cleaved 
by α-amylase, the smaller fragments produced were acted upon by α-glucosidase, 
which caused the ultimate release of the chromophore that was measured at 405 nm.  
Different concentrations of HH (5 and 10 µg/ml) were prepared in α- amylase Assay 
Buffer PH 6.9 and used as a negative control. The dose dependency of the HH extract 
on alpha amylase was measured using same negative control concentrations (5 and 10 
µg/ml). A volume of 2 µl alpha amylase activity solution was added to the positive 
control and test samples. A volume of 100 µl of the reaction mixture was added into 
each well and mixed. Optical density was measured immediately (To) at 405 nm to 
get OD To. The reaction was incubated at 25 °C for various times (5, 10, 15, 50, 25, 
30 and 35) minutes (Tı). Optical density was measured again at 405 nm to get OD Tı. 
The reaction kinetics was observed and the linear range for To-Tı was chosen. 
 
           Equation 4 
 
                
 
   
 
 
B is the nitrophenol amount obtained from Standard Curve (nmol).  
T is the time between T0 and T1 (min).  
V is the pre-treated sample volume added to the reaction well (ml). 
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 Alpha Glucosidase 3.4.4.2
 
Alpha Glucosidase inhibition of the HH aqueous extract was measured using a 
commercially available Glucosidase Activity Colorimetric Assay. The α-Glucosidase 
hydrolysed the substrate mix to release the p-nitrophenol that were measured 
calorimetrically (OD = 410 nm). This kit measured 0.1-10 mU of α-glucosidase 
activity in the samples. Different concentrations of HH (5 and 10 µg/ml) were 
prepared in α-Glucosidase Assay buffer pH 6.9 and used as a negative control. The 
dose dependency of the HH extract on alpha glucosidase was measured using same 
negative control concentrations (5 and 10 µg/ml). A volume of 2 µl Alpha 
glucosidase activity solutions was added to the positive control and test samples. A 
volume of 50 µl of the reaction mixture was added into each well and mixed. Optical 
density was measured immediately (To) at 410 nm to get ODTo. The reaction was 
incubated at 25 °C for different time period (5, 10, 15, 20, 25, 30 and 35) minutes 
(Tı). Optical density was measured again at 410 nm to get ODTı. The reaction 
kinetics was observed and the linear range for To-Tı was choosing. 
 
Equation 5  
                      
     
 
 
Sa = the slope of the enzyme activity (OD/min) in the sample well. 
Ss= slope of Standard Curve (OD/nmol) 
 V = sample volume added to the well (μl) 
 
3.5  Data analysis 
All data are reported as means ± SEM or median. Statistical differences among 
groups were analysed by analyses of Two-way ANOVA (non-parametric test) 
followed by Kruskal-Wallis test. Graphs and calculation were generated using Excel. 
P< 0.05 was considered as significant and data analysis was done using Graph Pad 
Prism version 5.1 for Windows (GraphPad Software, San Diego, CA, USA). 
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CHAPTER IV 
 
4 Results 
 
The pancreatic islet tumour cell line (RIN-5F) was cultured in RPMI 1640 medium in 
25 cm² and 75 cm² culture flasks at 37 
o
C under a 5 % CO2 humidified atmosphere 
and supplemented with 16 % foetal bovine serum (FBS). 
 
The RIN-5F cells were exposed to different concentrations of glucose (5, 10, 20, 
37.5, 50, 55, 74, and 92.3 mM) at different time periods of 1, 3, 6 and 24 hours. The 
RIN-5F cells were also exposed to different concentrations of HH (50, 100, 150, 200 
and 500 µ/ml) at different time periods of 1, 3, 6 and 24 hours. Cell proliferation was 
evaluated using crystal violet staining procedure and cell viability was evaluated 
using XTT assay. 
 
4.1 Cell proliferation of RIN-5F cell using crystal violet staining  
 
The cell proliferation of RIN-5F cells was tested by means of the crystal violet 
staining procedure after exposure to different concentrations of glucose or HH. 
 
4.1.1 Effect of Glucose on cell proliferation 
 
The results of the effect of different concentration of glucose (5, 10, 20, 37.5, 50, 55, 
74 and 92.3 mM) on RIN-5F cell proliferation at different exposure time of 1, 3, 6 
and 24 hours are shown in Figure 4.1 and in Table 4.1. Statistically the cell numbers 
in 5, 10, 20, 37.5, 55, 74 and 92.3 mM glucose were not significantly different (P > 
0.05) from the control group after 1, 3 and 6 hours. The cell numbers in 50 mM 
glucose after 1 hour (134±13%; P≤ 0.001) and 3 hours (128±19.2%; P ≤ 0.01) were 
significantly higher than the control group.  
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When cells were exposed for 24 hours, statically the cell numbers in 5 mM 
(79±2.4%; P ≤ 0.05), 10 mM (78±2.8%; P ≤ 0.05), 20 mM (79±2.45%; P ≤ 0.05), 
37.5 mM (75±4.6%; P ≤ 0.01), 50 mM, (73±4.6%; P ≤ 0.01), 55 mM, (70±2.6%; P ≤ 
0.001), 74 mM (70±4.3%; P ≤ 0.001) and 92.3 mM (66±2%; P ≤ 0.001) thus all 
glucose concentrations were significantly lower than the control group. 
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Figure  4.1. The effect of 1, 3, 6 and 24 hours exposure to glucose (5, 10, 20, 37, 5, 50, 55, 74 and 92.3 mM) on  RIN-5F cell 
proliferation using crystal violet staining. 
 
Values are indicated ( mean ± SD) as  a percentage of the respective control groups.The values are given in Table 4.1. 
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Table  4.1. The effect of 1, 3, 6 and 24 hours exposure to glucose (5, 10, 20, 37, 5, 50, 55, 74 and 92.3 mM) on RIN-5F cell proliferation 
using crystal violet staining. 
 
 1 H 3 H 6 H 24 H 
 
C 
 
100±0 
 
 
100±0 
 
 
100±0 
 
 
100±0 
 
5 
 
106±5.8 102±17 96±2.8 79±2.4* 
10 
 
108±9.2 103±13.7 89±6.4 78±2.8* 
20 
 
108±8.3 109±17 88±5.2 79±2.4* 
37.5 
 
118±16.9 111±18.7 90±5.8 75±4.6** 
50 
 
134±13.4*** 
 
128±19.2** 94±2.8 73±4.6** 
55 
 
94±4.2 
 
95±3.5 90±4.7 70±2.6*** 
74 
 
94.5±3.4 
 
90±3.5 93±4.7 70±4.3*** 
92.3 
 
93±3.4 
 
87±3.5 92±6.3 66±2*** 
Values are expressed as the mean ± SD. Cell numbers are expressed as a percentage of the respective control groups, Significant differences between the 
glucose  (5, 10, 20, 37, 5, 50, 55, 74 and 92.3 mM) groups  and  the control groups using (2 way ANOVA) are indicated; *P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001. 
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4.1.2 Effect of HH on cell proliferation 
 
The results of the effects of HH on RIN-5F cells proliferation after exposure to 
different concentrations (50, 100, 150, 200 and 500 µg/ml) of HH for 1, 3, 6 and 24 
hours are shown in Figure 4.2 and in Table 4.2. Statistically the cell numbers in 50, 
100 and 150 µg/ml of HH were not significantly different (P > 0.05) from the control 
group after 1, 3, 6 and 24 hours. 
 
When cells were exposed to 200 µg/ml HH for 1 hour (116±4%; P ≤ 0.01), 3 hours 
(119±3%; P ≤ 0.01) and 6 hours (120±13.1%; P ≤ 0.001) cell proliferation was 
significantly higher than the control group. The cell numbers in 500 µg/ml HH treated 
samples after 1 hour (117±7%; P ≤ 0.01), 3 hours (120±6.9%; P ≤ 0.001) and 6 hours 
(135±10.6%; P ≤ 0.001) were also significantly higher than the control group. Cells 
exposed for 24 hours were not significantly different (P > 0.05) from the control 
group.  
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Figure  4.2. The effect of 1, 3, 6 and 24 hours exposure to HH (50, 100, 150, 200 and 500 µg/ml) on RIN-5F cell proliferation using crystal 
violet staining. 
Values are indicated ( mean ± SD) as a percentage of the respective control groups.The actual values are given in Table 4.2. 
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Table  4.2. The effect of 1, 3, 6 and 24 hours exposure to HH (50, 100, 150, 200 and 500 µg/ml) on RIN-5F cell proliferation using crystal 
violet staining. 
 
 1 H 3 H 6 H 24 H 
C 100±0 100±0 
 
100±0 
 
100±0 
 
50 103±3.0 
 
106±3.02 
 
101±9.9 
 
93±3.11 
 
100 103±3.3 109±3.3 
 
105±7 
 
91±3.7 
 
150 105±6.7 
 
108±6.7 
 
112±10.3 
 
93±4 
 
200 116±4** 
 
119±3.0** 
 
120±13.1*** 
 
95±2.7 
 
500 117±7** 
 
120±6.9*** 
 
135±10.6*** 
 
95±2.9 
 
 
Values are expressed as the mean ± SD. Cell numbers are expressed as a percentage of the respective control groups. Significant differences between the 
HH (50, 100, 150, 200 and 500 µg/ml) groups and the control groups using (2 way ANOVA) are indicated; ** P ≤ 0.01, *** P ≤ 0. 
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4.2 Viability of RIN-5F cell using XTT assay 
 
The cell viability or bioreductive capacity of RIN-5F cells was tested by mean of the 
XTT assay after exposure to different concentrations of glucose or HH. 
 
4.2.1 Effect of Glucose on cell viability 
 
The results of the effect of glucose on RIN-5F cell viability after exposure to different 
concentrations (5,10, 20, 37.5, 50, 55, 74 and 92.3 mM) of glucose for 1, 3, 6 and 24 
hours are presented in Figure 4.3 and in Table 4.3. Statistically the cell viability in 5, 
10 and 20 mM glucose were  not significantly different (P  > 0.05) from the control 
group after 1, 3 and 6 hours. When the cells were exposed to 5mM glucose 
(79±2.5%; P ≤ 0.05%), 10 Mm glucose (78±1.7%; P ≤ 0.05%) and 20 mM glucose 
(79±2.5%; P ≤ 0.05%) for 24 hours the viability was significantly lower than the 
control group. 
 
When the cells were exposed to 37.5 mM glucose for 3 hours the cell viability were 
not significantly different (P > 0.05) from the control group, while the cell numbers 
after 6 hours (79±8.1%; P ≤ 0.05) and 24 hours (76±3.8%; P ≤ 0.01) were 
significantly lower than the control group, and the cell viability after 1 hour 
(119±9.8%; P ≤ 0.05) was significantly higher than the control group.  
 
When cells were exposed to 50 mM glucose for 1 hour and 3 hours the viability of 
the cells was significantly higher than the control group (133±12.6%; P ≤ 0.001 and 
128±16%; P ≤ 0.001 respectively). Cell viability after 6 hours (80±10.4%; P ≤ 0.05) 
and 24 hours (75±4.2%; P ≤ 0.01) was significantly lower than the control group. 
When cells were exposed to 55 mM glucose the cell viability after 1 and 3 hours was 
not significantly different (P > 0.05) from the control group, while, the cell viability 
after 6 hours (81±6.7%; P ≤ 0.05) and 24 hours (69±2.4%; P ≤ 0.001) was 
significantly lower than the control group. 
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When cells were exposed to 74 mM glucose the cell viability after 1, 3 and 6 hours 
was not significantly different (P > 0.05) from the control group, the viability of the 
cell after 24 hours (74±5.9%; P≤0.01) was significantly lower than the control group. 
When exposed to 92.3 mM glucose, cell viability after 1 and 3 hours was not 
significantly different (P > 0.05) from the control group, while the cell viability after 
6 hours (81±6.8%; P ≤ 0.05) and 24 hours (70±6.5%; P ≤ 0.001) was significantly 
lower than the control group.  
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Figure  4.3. The effect of 1, 3,, 6 and 24 hours exposure to glucose (5, 10, 20, 37, 5, 50, 55, 74 and 92.3 mM) on  RIN-5F cell  viability using 
the XTT assay. 
Values are indicated (mean ± SD) as a percentage of the respective control groups. The actual values are given in Table 4.3. 
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Table  4.3. The effect of 1, 3, 6 and 24 hour’s exposure to glucose (5, 10, 20, 37, 5, 50, 55, 74 and 92.3 mM) on RIN-5F cell viability using 
the XTT assay. 
 
 1 H 3 H 6 H 24 H 
C 100±0 100±0 100±0 
 
100±0 
 
5 106±5.7 102±17.4 91±4.8 79±2.5* 
10 110±9.1 104±17.4 89±4.2 78±1.7* 
20 111±9.1 109±17.3 88±5.6 79±2.5* 
37.5 119±9.8* 115±17 79±8.1* 76±3.8** 
50 133±12.6*** 128±16*** 80±10.4* 75±4.2** 
55 95±3.4 95±3.3 81±6.7* 69±2.4*** 
74 93±3.4 90±3.3 84±7.2 74±5.9** 
92.3 90±3.4 86±3.3 81±6.8* 70±6.5*** 
Values are expressed as the mean ± SD. Cell numbers are expressed as a percentage of the respective control groups. Significant differences between the 
glucose (5, 10, 20, 37.5, 50, 55, 74 and 92.3 mM) groups  and  the control groups using (2 way ANOVA) are indicated; *P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001. 
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4.2.2  Effect of HH on cell viability 
 
The results for the effect of HH on RIN-5F cell viability after exposure to different 
concentrations (50, 100, 150, 200 and 500 µg/ml) of HH for periods of 1, 3, 6 and 24 
hours are shown in Figure 4.4 and in Table 4.4. Statistically the cell viability in 50, 
100 and 150 µg/ml HH was not significantly different (P > 0.05) from the control 
group after 1, 3, 6 and 24 hours. 
 
When cells were exposed to 200 µg/ml HH the viability of the cell after 1 hour 
(117±3.6%; P ≤ 0.05), 3 hours (120±3.6%; P ≤ 0.01) and 6 hours (119±14%; P ≤ 
0.05) was significantly higher than the control group, while the cell viability after 24 
hours was not significantly different (P > 0.05) from the control group. 
 
When cells were exposed to 500 µg/ml HH the cell viability after 1 hour (118±3.3%; 
P ≤ 0.01), 3 hours (121±3.3%; P ≤ 0.01) and 6 hours (130±12%; P ≤ 0.001) was 
significantly higher than the control group, but the viability of the cells after 24 hours 
was not significantly different (P > 0.05) from the control group.  
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Figure  4.4. The effect of 1, 3, 6 and 24 hours exposure to HH (50, 100, 150, 200 and 500 µg/ml) on RIN-5F cell viability using the XTT 
assay. 
Values are indicated as the mean ± SD as a percentage of the respective control groups. The actual values are given in Table 4.4. 
 
 
 
 
 
 
 
 
 
58 
 
Table  4.4. The effect of 1, 3, 6 and 24 hours exposure to HH (50, 100, 150, 200 and 500 µg/ml) on RIN-5F cell viability using the XTT 
assay. 
 
 1 H 3 H 6 H 24 H 
C 100±0 100±0 
 
100±0 
 
100±0 
 
50 101±3.0 
 
104±3.9 
 
101±6.9 
 
96±10.4 
 
100 101±3.1 104±3.9 
 
105±9.2 
 
95±7.2 
 
150 104±3.1 
 
107±3.1 
 
112±14 
 
92±9.7 
 
200 117±3.6* 
 
120±3.6** 
 
119±14* 
 
94±7.4 
 
500 118±3.3** 
 
121±3.3** 
 
130±12*** 
 
96±14.6 
 
 
 
Values are expressed as the mean ± SD. Cell numbers are expressed as a percentage of the respective control groups. Significant differences between the 
HH (50, 100, 150, 200 and 500 µg/ml) groups and the control groups using (2 way ANOVA) are indicated; *P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. 
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4.3 Insulin secretion studies 
 
The effect of glucose and HH on RIN-5F cell insulin secretion was evaluated. The 
cells were exposed to two concentrations of HH, 100 μg/ml and 500 μg/ml. They 
were also exposed to two concentrations of glucose, 2 mM (low glucose) and 50 mM 
(high glucose). The exposure time was 30 minutes and 90 minutes. 
 
4.3.1 Insulin secretion after 30 minutes  
 
The insulin secretion data for RIN-5F cells which were exposed to different 
concentrations of glucose, 2 mM and 50 mM, are presented in Figure 4.5. Statistically 
the insulin secretion in 2 mM glucose (1.31±0.23 mIU/mg protein; P ≤ 0.05) and 50 
mM glucose (1.51±0.14 mIU/mg protein; P ≤ 0.01) was significantly higher than the 
control group (0.97±0.12 mIU/mg protein). The Insulin secretion in 2 mM glucose 
was not significantly different (P >0.05) from that in 50 mM glucose. 
 
C
o
n
tr
o
l
2
 m
M
 g
lu
c o
se
5
0
 m
M
 g
lu
c o
se
 
0 .0
0 .5
1 .0
1 .5
2 .0
*
* *
I
n
s
u
li
n
 s
e
c
r
e
t
io
n
(
m
I
U
/m
g
 p
r
o
t
e
in
)
G lu c o s e  c o n c e n t r a t io n  (m M )
 
Figure  4.5. Insulin secretion by RIN-5F cells exposed to different glucose 
concentrations for 30 min. 
Values are the mean ± SD. *P ≤ 0.05, ** P ≤ 0.01, compared to control group. 
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The results of RIN-5F cells which were exposed to different concentrations of HH, 
100 μg/ml and 500 μg/ml for 30 minutes are presented in Figure 4.6. Statistically the 
insulin secretion in 100 μg/ml HH (2.17±0.13 mIU/mg protein; P ≤ 0.01) and the 
insulin secretion in 500 μg/ml HH (3.9±0.11 mIU/mg protein; P ≤ 0.001) was 
significantly higher than the control group (0.97±0.12 mIU/mg protein). The insulin 
secretion in the 500 μg/ml treated samples was significantly higher (P ≤ 0.001) than 
the 100 μg/ml HH treated group. 
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Figure  4.6. Insulin secretion by RIN-5F cells exposed to different HH concentrations 
for 30 min. 
Values are the mean ± SD. **P ≤ 0.01, *** P ≤ 0.001, compared to control group. 
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Insulin secretion by RIN-5F cells exposed to 2mM (low glucose) in combination with 
either 100 μg/ml HH or 500 μg/ml HH for 30 minutes are shown in Figure 4.7. 
Statistically the insulin secretion in 2 mM glucose +100 μg/ml HH (2.37±0.15 
mIU/mg protein; P ≤ 0.001) was significantly higher than the 2 mM glucose 
(1.31±0.23 mIU/mg protein). Insulin secretion in 2 mM glucose +500 μg/ml HH 
(1.30±0.14 mIU/mg protein; P > 0.05) was not significantly different from the 2 mM 
glucose (1.31±0.23 mIU/mg protein). The insulin secretion by 2 mM glucose + 500 
μg/ml HH treated samples was significantly lower (P > 0.001) than 2 mM glucose 
+100 μg/ml HH treated group. 
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Figure  4.7. Insulin Secretion by RIN-5F cell exposed to 2Mm glucose and different 
HH concentrations for 30 min. 
Values are the mean ± SD. *** P ≤ 0.001, compared to 2 mM glucose group. 
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The RIN-5F cells exposed to 50 mM (high) glucose in combination with either 100 
μg/ml HH or 500 μg/ml HH for 30 minutes are shown in Figure 4.8. Statistically the 
insulin secretion in 50 mM glucose + 100 μg/ml HH (0.56±0.08 mIU/mg protein; P ≤ 
0.001) and 50 mM glucose + 500 μg/ml HH (0.34±0.03 mIU/mg protein; P ≤ 0.001) 
was significantly lower than 50 mM glucose only (1.51±0.14 mIU/mg protein). The 
insulin secretion by 50 mM glucose + 500 μg/ml HH was not significantly different 
(P > 0.05) from the 50 mM glucose + 100 μg/ml HH treated group.  
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Figure  4.8. Insulin Secretion by RIN-5F cell exposed to 50mM glucose and different 
HH concentrations for 30 min. 
Values are the mean ± SD. *** P ≤ 0.001, compared to 50 mM glucose group. 
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4.3.2  Insulin secretion after 90 minutes 
 
The insulin secretion data for the RIN-5F cells exposed to different concentrations of 
glucose, 2 mM and 50 mM for 90 minutes are presented in Figure 4.9. Statistically 
the insulin secretion in 2 mM glucose (2.27±0.17 mIU/mg protein; P>0.05) was not 
significantly different from the control group (1.81±0.17 mIU/mg protein). The 
insulin secretion in 50 mM glucose (2.9±0.17 mIU/mg protein; P ≤ 0.001) was 
significantly higher than the control group (1.81±0.17 mIU/mg protein). The Insulin 
secretion in 2 mM glucose was not significantly different (P > 0.05) from the 50 mM 
glucose treated samples. 
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Figure  4.9. Insulin secretion by RIN-5F cell exposed to different glucose 
concentrations for 90 min. 
Values are the mean ± SD. *** P ≤ 0.001, compared to control group. 
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The insulin secretion results of the RIN-5F cells which were exposed to different 
concentrations of HH, 100 μg/ml and 500 μg/ml, are presented in Figure 4.10. 
Statistically the insulin secretion in 100 μg/ml HH (4.3±0.17 mIU/mg protein; P ≤ 
0.01) and 500 μg/ml HH (7.87±0.17 mIU/mg protein; P ≤ 0.001) were significantly 
higher than the control group (1.81±0.17 mIU/mg protein). The insulin secretion by 
cells exposed to 500 μg/ml HH was significantly higher (P ≤ 0.01) than the cells 
exposed to 100 μg/ml HH group. 
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Figure  4.10. Insulin Secretion by RIN-5F cells exposed to different HH 
concentrations for 90 min. 
Values are the mean ± SD. **P ≤ 0.01, *** P ≤ 0.001, compared to control group. 
 
 
Insulin secretion by RIN-5F cells exposed to 2 mM (low) glucose in combination 
with either 100 μg/ml HH or 500 μg/ml HH are shown in Figure 4.11.Statistically the 
insulin secretion by 2 mM glucose + 100 μg/ml HH (4.69±0.16 mIU/mg protein; P ≤ 
0.001) was significantly higher than 2 mM glucose only (2.27±0.17 mIU/mg protein), 
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while the insulin secretion by 2 mM glucose + 500 μg/ml HH (2.56±0.17 mIU/mg 
protein; P > 0.05) was not significantly different from that in 2 mM glucose treated 
cells (2.27±0.17 mIU/mg protein). The insulin secretion by 2 mM glucose + 500 
μg/ml HH was significantly lower (P ≤ 0.001) than 2 mM glucose +100 μg/ml HH 
treated group. 
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Figure  4.11. Insulin Secretion by RIN-5F cells exposed to 2mM glucose and different 
HH concentrations for 90 min. 
Values are the mean ± SD. ** P ≤ 0.01, *** P ≤ 0.001, compared to 2 mM glucose group. 
 
 
Insulin secretion by cells exposed to 50 mM (high) glucose and either (100 μg/ml HH 
or 500 μg/ml HH) are shown in Figure 4.12. Statistically the insulin secretion of cells 
exposed to 50 mM glucose + 100 μg/ml HH (1.09±0.19 mIU/mg protein; P ≤ 0.001) 
and 50 mM glucose + 500 μg/ml HH  (0.59±0.18 mIU/mg protein; P ≤ 0.001) was 
significantly lower than that of cells exposed to 50 mM  glucose (2.91±0.17 mIU/mg 
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protein). The insulin secretion in 50 mM glucose + 500 μg/ml HH was not 
significantly different (P ≤ 0.05) from the 50 mM glucose + 100 μg/ml HH group. 
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Figure  4.12. . Insulin Secretion by RIN-5F cells exposed to 50mM glucose and HH 
different concentrations for 90 min. 
Values are the mean ± SD. *** P ≤ 0.001, compared to the 50 mM glucose group. 
 
4.4  Effect of HH on alpha amylase and alpha glucosidase activity 
 
4.4.1 Effect of HH on alpha amylase activity 
 
Figure 4.13 shows the standard curve generated for the determination of alpha 
amylase activity.  
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Figure  4.13. Nitrophenol standard curve used for determining α-amylase activity. 
 
The standard curve shows a linear relationship between the nitrophenol concentrations and 
the absorbance. 
Figure. 4.14. shows the effect of the different concentrations of HH (5 µg/ml and 10 
µg/ml) on alpha amylase activity. In the presence of 5 µg/ml HH, amylase activity 
was not significantly different from the α-amylase positive control (1459±185 U/ml 
vs 1212±109 U/ml; P > 0.05). In the presence of 10 µg/ml HH, alpha amylase activity 
was significantly lower (922±117 U/ml vs 1459±185 U/ml; P ≤ 0.01) than that of the 
positive control. The results were expressed as the mean± SEM value of alpha 
amylase activity, in 3 different experiments. 
 
y = 0.0177x + 0.0929 
R² = 0.9973 
0
0.1
0.2
0.3
0.4
0.5
0.6
0 10 20 30
A
b
so
rb
an
ce
 (
4
0
5
 n
m
) 
Nitrophenol (nmol) 
 Nitrophenol STD
 
 
 
 
68 
 
. 
p
o
s i
t i
v
e  
c o
n
tr
o
l 
(A
)
5
 µ
g
/m
l 
H
H
 +
 A
1
0
 µ
g
/m
l 
H
H
 +
 A
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0

-
a
m
y
la
s
e
 a
c
t
iv
it
y
 (
m
U
/m
l)
* *
 
Figure  4.14. Alpha amylase activity in the presence of two concentrations of HH. 
Values are the mean ± SEM.  HH: Hypoxis hemerocallidea, A: Alpha amylase. ** P ≤ 
0.01, compared to positive control. 
 
4.4.2 Effect of HH on alpha glucosidase activity 
 
Figure.4.15. shows the standard curve generated for determination of alpha glucosidase 
activity. 
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Figure  4.15. p- Nitrophenol standard curve used for determining α-glucosidase activity 
 
The standard curve shows a linear relationship between the nitrophenol concentrations and 
the absorbance. 
 
Figure. 4.15. shows the effect of the different concentrations of HH (5 µg/ml and 10 
µg/ml) on alpha glucosidase activity. HH significantly decreased the activity of the α-
glucosidase positive control (1.84± 0.12 U/ml vs 0.12± 0.3 U/ml; P ≤ 0.001) in the 
presence of 5 µg/ml HH, and to 0.13± 0.3 U/ml (P ≤ 0.001) in the presence of 10 
µg/ml HH. The results were expressed as the mean± SEM value of alpha amylase 
activity, in 3 different experiments. 
 
y = 0.0106x + 0.099 
R² = 0.9943 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 50 100 150
A
b
so
rb
an
ce
 (
4
1
0
 n
m
) 
p-Nitrophenol (nmol) 
 
 
 
 
70 
 
p
o
s i
t i
v
e  
c o
n
tr
o
l 
(B
)
5
 m
g
/m
l 
H
H
 +
 B
 
1
0
 m
g
/m
l 
H
H
 +
 B
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5

-
g
lu
c
o
s
id
a
s
e
 a
c
t
iv
it
y
 (
U
/m
l)
* * * * * *
 
Figure  4.16. . Alpha glucosidase activity in the presence of two concentration of HH. 
Values are the mean ± SEM. HH: Hypoxis hemerocallidea, G: Alpha glucosidase. *** P ≤ 
0.001, compared to the positive control. 
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CHAPTER V 
 
5 Discussion 
 
The main aim of this research was to study the possible hypoglycemic effect using 
RIN-5 F pancreatic tumor cells. To accomplish this, the study design was divided into 
three parts: (1) to test whether exposure of RIN-5F cells to glucose or the HH 
aqueous extract will effect cell proliferation and cell viability, (2) to test whether the 
HH extract have an effect on insulin secretion and (3) to test whether the HH extract 
has an effect on alpha amylase and alpha glucosiadase enzyme activity. The HH 
aqueous extract caused significant reductions in the blood glucose levels of the fasted 
normal and STZ-treated diabetic rats (Mahomed & Ojewole, 2003). Erlwanger & 
Cooper (2008) found significant antidiabetic effects starting at 100 mg/kg in both 
normoglycemic and hypoglycemic rats. A previous study also indicated that the HH 
has anti diabetic properties and suggested that the effect is due to HH having 
antioxidant properties (Katerere & Eloff, 2008). While it is likely that the 
hypoglycemic effect of the plant extract is largely due to its sterolin content and/or 
phytosterols, the exact mechanism of its hypoglycemic action is still obscure and will 
have to await further studies (Mahomed & Ojewole, 2003).  
 
5.1  Effect of glucose and HH on cell proliferation and cell viability 
 
5.1.1 Proliferation studies 
 
The present study was to clarify whether prolonged in vitro exposure of RIN-5F cells 
to glucose and HH impairs mitosis and growth of these cells. The energy to perform 
cell division, growth, and replacement of damaged effected cells, is derived from the 
aerobic metabolism of glucose. The energy required for nuclear division appears to be 
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fully or partly derived from the anaerobic metabolism of glucose (Holt, 1980; Greiner 
et al., 1994). 
 
The glucose stimulates cell cycle progression, which  implies that an increase in 
glucose could stimulate cell proliferation and division (Salpeter et al., 2010). Figure 
4.1. and Table 4.1 showed mostly a decrease in cell proliferation especially after the 
24 hour exposure time period where a significant decrease was observed. The only 
significant increase in cell proliferation was observed in the cells exposed to 50 mM 
glucose for 1 hour and 3 hours. This would imply that an increase in glucose could 
inhibit cell proliferation and division when the cells are exposed for at least 24 hours. 
Salpeter et al (2010) reported that β-cells are quick to regain their capacity of re-
entering the cell cycle post-mitosis and implicate glucose control of cyclin D2 
expression in the regulation of cell cycle progression. In previous studies, glucose 
appears to be beneficial for maintaining cell metabolism and proliferation in vitro. A 
recent study showed that the culture expansion under low glucose conditions protect 
the desired characteristics for tissue formation (Heywood et al., 2014). Cell 
proliferation is modulated in accordance with its metabolic status, and this will 
interfere in the cell’s biology and function, since the signal transduction, genetic 
expression, and metabolism depend on protein transformation processes (Fock et al., 
2010). 
 
Figure 4.2. and Table 4.2 show proliferation differences of HH on RIN5-F cells 
which may play an important role in the administration of HH in traditional medicine 
for the treatment of disease. An increase in cell proliferation was observed at 
concentrations of 200 mg/ml HH higher for 1, 3 and 6 hours. Thus would imply 
adaptation to the HH extract and survival of these cells. When the cells were exposed 
to the HH extract over 24 hours, a slight but not significant decrease in cell 
proliferation was seen. The decrease could be due to cytotoxic effects since 
cytotoxicity on  MDA-MB-231 human breast cancer cells are shown to be due to the 
presence of β-sitosterol or other unknown active compounds in the chloroform HH 
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extracts (Awad & Fink, 2000). Boukes & van de Venter (2011) demonstrated that the 
mechanism by which HH induced cytotoxicity in cancer cells could be due to 
apoptosis and cell cycle arrest. This is the first time that cytotoxicity of HH is studied 
on RIN-5F cells and the mechanisms of possible cytotoxic effects must be elucidated. 
 
5.1.2 Viability studies 
 
Mitochondrial dehydrogenase activity is often used to measure cell viability, 
including β-cell viability (Maechler & Wollheim, 2001). β-cell mitochondria serve as 
fuel sensors, generating factors that couple nutrient metabolism to the exocytosis of 
insulin-containing vesicles (Maechler & Wollheim, 2001). This study was to clarify 
whether prolonged in vitro exposure of RIN-5F cells to glucose and HH 
concentration impairs the viability of these cells by affecting mitochondrial 
dehydrogenase activity. Findings displayed in Figure 4.3 and Table 4.3 show that cell 
viability was decreased significantly by glucose after 6 hours and 24 hours exposure. 
An increase in cell viability was observed at concentrations below 50 mM glucose, in 
the cells exposed for 3 hours or less. Although slight, the increase in viability 
observed at 37.5 and 50 mM glucose was significant, and most probably due to an 
increase in mitochondrial dehydrogenase activity (Berridge et al., 1996). A 
significant decrease was seen in cells exposed to glucose for 24 hours at all 
concentrations tested and cells exposed to glucose for 6 hours at concentrations above 
37.5 mM glucose since glucose can influence cyclin D2 expression in cell growth 
control (Salpeter et al., 2010).  This decrease of cell viability after 24 hours could be 
due to down regulation of cyclin D2 that prevent replicated β-cells from returning to 
the pool of dividing cells (Salpeter et al., 2010).   
 
Figure 4.4 and Table 4.4 show the cell viability of HH on RIN5-F cells which may 
play an important role in the administration of HH in patients. An increase in cell 
viability was observed at concentrations of 200 µg/ml and 500 µg/ml if cells were 
exposed for 6 hours or less. This increase in cell viability could be indicative of a 
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marked increase  in the activity of the mitochondrial dehydrogenase and electron 
carriers which indicates that this plant extract may target the mitochondria of the 
pancreatic cell (Scaduto & Grotyohann, 1999). When the cells were exposed to the 
HH extract over 24 hours, HH did not affected cell viability significantly and only a 
slight but insignificant decrease in cell viability was observed. This could ascribed to 
cellular stress, that leads to a decrease in mitochondrial dehydrogenase activity 
(Berridge et al., 1996). Cyclin D2 together with cyclin Dependent kinase 4 (cdk4) is 
required for cell cycle progression. Inhibition of the cyclin D2 and (cdk4) complex 
leads to the induction of a cell cycle block that can influence cell proliferation and 
ultimately cell proliferation. 
 
Compared to the cell proliferation, the cell viability seems here to be slightly more 
sensitive in detecting the metabolic activity of the RIN-5F cells. Using the XTT 
assay, cells exposed to glucose showed a possible significant increase in the activity 
of the mitochondrial dehydrogenases by 37.5 mM and 50 mM glucose (Table 4.3), 
while the crystal violet assay showed a significant increase in cell proliferation 
starting from 50 mM glucose (Table 4.1). However, this difference in the sensitivity 
of both assays may be also a result of different passage of cells used. Using the XTT 
assay results in Table 4.4, cells exposed to HH extract showed a significant increase 
in the activity of the mitochondrial dehydrogenases after exposure to 200µg/ml HH 
and 500 µg/ml after 3 and 6 hours. 
 
These results show a marked increase in the cell viability and cell proliferation when 
exposed to high glucose concentrations and high dose of HH extract for short time 
period 1, 3 and 6 hours. Alteration of cyclin abundance is sufficient to change the rate 
of cell cycle progression, since over expression of G1 cyclins such as cyclin D 
accelerates cells through G1. Conversely, inhibition of their function can prevent 
entry into the S phase (Musqrove et al., 1988). It is possible what an initial increase 
in cyclin D2 levels by the higher glucose concentrations stimulated cell cycle 
progression, while continues exposure (24 hours) induced a depletion in cyclin D2 
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and mitochondrial dehydrogenase causing a decrease in cell proliferation and cell 
viability.  
   
5.2  Effect of HH on insulin secretion 
 
The purpose of the study was also to evaluate the effect of HH on RIN-5F cell insulin 
secretion.  When the demand for insulin is increased by physiological or pathological 
changes, β-cells can adapt by enhancing insulin secretion via increased β-cell 
function and/or increased β-cell mass (Andrali et al., 2008; Leibiger et al., 2008). 
Inadequate adaptation leads to the development of hyperglycemia and eventually 
diabetes mellitus (Chiasson et al., 2003). An antidiabetic agent could exert a 
beneficial effect in the diabetic situation by enhancing insulin secretion and/or by 
improving/mimicking insulin action (Gray & Flatt, 2007). The RIN-5F cells are the 
most important cells in secretion of insulin and secretion of small amounts of 
glucagon and somatostatin (Poitout et al., 1996). 
 
Glucose stimulated insulin secretion in low (2 mM) and high (50 mM) concentration 
for 30 minutes (Figure 4.5).  Also shown (Figure 4.9) is increased insulin secretion 
from RIN5F cells after exposed to high glucose (50 mM) after 90 minutes, while, 
insulin secretion after exposed to low glucose (2 mM) was no significant difference 
from the control group. Interestingly, there was not significantly different between 
high glucose (50 mM) and low glucose (2 mM) after exposed of RIN-5F cells after 
30 minutes and 90 minutes. The result of this study is in agreement with that of 
Purrello et al., (1989) who also observed increased insulin secretion in the presence 
of different concentration, (5.5 mM) and (16.7 mM) of  glucose when comparing to 
the control group. 
 
Henquin (2004) demonstrate of that the blockade of KATP channels in the plasma 
membrane of β-cells is a key step in the stimulation of insulin release by glucose and 
by many pharmacological components. This result in stimulation the Ca
+2
 influx, and 
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increase the cytosolic concentration of free Ca
+2
, which constitutes the triggering 
signal to induce exocytosis of insulin granules. The mechanism of glucose-induced 
desensitization in β-cells is not known. Evidence indicates that this phenomenon is 
not a consequence of impaired insulin synthesis (Purrello et al., 1989). The 
antihyperglycemic activity of HH achieved through insulin secretory potentiation 
may be due to the presence of the β- sitosterol (Farmer et al., 2012). 
 
The present study has also shown the beneficial use of HH in inducing insulin 
secretion from pancreatic cells. Findings displayed in Figure 4.6 show that insulin 
secretion was increased from RIN5F cells after exposure to low HH (100 µg/ml) or 
high HH (500 µg/ml) for 30 minutes. Exposure of RIN5-F cells to HH for 90 minutes 
caused a further increase in insulin secretion from (4.3±0.17 mIU/mg protein; P ≤ 
0.01) in 100 µg/ml, to (7.87±0.17 mIU/mg protein; P ≤ 0.001) in 500 µg/ml (Figure 
4.10). At both 30 minutes and 90 minutes, insulin secretion was significantly higher 
when cells where exposed to 500 µg/ml HH compared to 100 µg/ml HH (Figure 4.6 
and Figure 4.10). HH significantly increased glucoses stimulated insulin secretion by 
RIN-5F cells. The stimulation of insulin secretion and potential glucose absorption by 
RIN-5F was dependent on the dose and severity of hyperglycemia. Steroids might 
stimulate the islets to secrete insulin and might increase sensitivity to insulin, thereby 
enhancing glucose uptake. Similarly, Achrekar et al (1991) reported that an aqueous 
extract of the pulp of Eugenia jambolana stimulated the release of insulin both in 
vitro and in vivo. 
 
 Figure 4.7 illustrates that in the presence of the low HH concentration (100 µg/ml, 30 
minutes) insulin secretion is higher than at the 2 mM glucose concentration, while, at 
the high HH concentration (500µg/ml, 30 minutes) insulin secretion was not 
significantly different from the 2mM glucose. It is important to note that at the low 
HH concentration (100µg/ml) insulin secretion is higher than at the high HH 
concentration (500µg/ml). Similar results are obtained after 90 minutes finding 
displayed in Figure 4.11. We do not know whether the rate of insulin secretion 
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remained constant over the 90 minutes. It is possible that the β-cells became either 
desensitized or exhausted. There are two clear concepts for glucose-induced 
desensitizations, the first is a consequence of functional changes in the β-cell that 
impair glucose-recognition. The second, a consequence increased secretory activity  
in the β-cell leads to a depletion of releasable insulin (Rustenbeck, 2002). Increase 
insulin secretion from β-cells occurs by two various mechanisms. The first, under 
high-glucose conditions, proceeded by a classical secretory pathway involving KATP 
channel closure, membrane depolarization, calcium channel gating, and calcium 
mobilization. The second mechanism, under low-glucose conditions, may occurs 
independently of glucose metabolism (Ammälä et al., 1993; Haidar et al., 2004). 
 
In the presence of high-glucose (50 mM), at both 30 minutes and 90 minutes, insulin 
secretion was significantly decreased when cells where exposed to low concentration 
of HH (100 µg/ml) and high concentration of HH (500 µg/ml) (Figure 4.8 and Figure 
4.12), however, there was no significant difference between low HH (100 µg/ml) and 
high HH (500 µg/ml). The significant decrease in insulin secretion in the presence of 
high-glucose (50 mM) for a long period caused cell dysfunction and may induce cell 
apoptosis in type 2 diabetes. High glucose has many implications, initially resulting 
in ―glucose hypersensitization‖ and later apoptosis, by different mechanisms. High 
glucose does not induce or activate IL-1, NF-B, or inducible nitric oxide synthase in 
rat or human cells. This will have to be tested in RIN-5F cells, especially in the 
presence of HH (Miriam, cnop et al., 2005). 
 
5.3  Effect of HH on α-amylase and α-glucosidase activity 
 
The inhibition of α-amylase activity and α-glucosidase activity is considered to be an 
effective strategy for the control of blood glucose levels by slowing the digestion of 
glucose (Tundis et al., 2010). As shown in Figure 4.14 the HH extract inhibited α-
amylase enzyme activity. The maximum inhibition was 37 % at a concentration of 10 
mg/ml, while 5 mg/ml HH failed to produce significant inhibition.  Moreover, from 
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Figure 4.16 It is clear that the in vitro α-glucosidase inhibitory studies demonstrated 
that HH extract had significant α- glucosidase inhibitory activity. The maximum 
inhibition was 93.5 % at a concentration of 10 mg/ml while 5 mg/ml inhabit α-
glucosidase activity by 93 %. Mcdougall et al., (2005) showed that strawberry and 
raspberry extracts were more effective as α-amylase inhibitors than blueberry, 
blackcurrant, or red cabbage. Conversely, α-glucosidase was more readily inhibited 
by blueberry and blackcurrant extracts. 
 
 The extent of inhibition of α- glucosidase was related to their anthocyanin 
components. Different polyphenolic components of these fruits may influence 
different steps in starch digestion in a synergistic manner (Honda & Hara, 1993). 
Some medicinal plants such as Horsfieldia amygdalina,  has been reported to have 
anti-diabetic activity when assessed using presently available experimental 
techniques (Honda & Hara, 1993; Grover et al., 2002; Latha et al., 2004; Mai et al., 
2007). Sweet potato, berry, and polyphenols from tea have a significant antioxidant 
activity since various phenolic compounds have been generally accepted as anti-
oxidant agents, it has been shown that the activity of α-glucosidase and α-amylase is 
effectively inhibited by anti-oxidant agents. A previous study also indicated that the 
HH have anti diabetic properties and it also suggests that the effect is due  to HH 
having antioxidant properties (Katerere and Eloff, 2008). Therefore, these findings 
indicate that the differences in the inhibitory effects of HH on the activity of α-
glucosidase and α-amylase could be due to the levels of anti-oxidant compounds in 
their extracts.  
  
Mahomed & Ojewole (2003) reported that the antidiabetic activities of HH using 800 
mg/kg aqueous extract causes 20- 30% and 48-54 % reductions in the blood glucose 
level of fasted normal and STZ-treated diabetic rats. Both the aqueous and ethanolic 
extracts of HH are able to scavenge hydroxyl radicals through their anti-oxidant 
property by the presence of hypoxidae (Nair et al (2007). 
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5.4 Conclusions 
 
Our objectives were:  
 To determine the toxicity of Hypoxis hemerocallidea  and glucose on 
pancreatic RIN-5 F cell viability  
 To determine whether Hypoxis hemerocallidea can increase insulin secretion 
from the pancreatic RIN-5 F cells. 
 To determine whether Hypoxis hemerocallidea can inhibit the activity of α-
amylase and α -glucosidase.  
(Evaluation of the ability to plant extract to increase glucose uptake by cells falls 
outside the scope of this thesis) 
 
  A marked increase in the cell viability and cell proliferation was found when RIN-
5F cells were exposed to high glucose concentrations and high dose of HH extract for 
a short time period (1, 3 and 6 hours). The HH aqueous extract has good potential for 
the management of blood glucose levels due to its ability to inhibit α-amylase activity 
and α-glucosidase activity. The HH aqueous extract increased insulin secretion under 
our basic experimental conditions and in the presence of low glucose levels, but not at 
high (50 mM) glucose concentrations. Insulin secretion in the presence of different 
glucose concentrations, in the presence of HH, needs further investigation. It would 
be particularly important to test the effect of HH on insulin secretion when the 
concentration of glucose in the medium is between 10 and 25 mM, levels more likely 
to be found in uncontrolled diabetes. 
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